Francisco Vega, MD PhD

Peer-Reviewed Articles

1. Nieto Y, Banerjee P, Kaur I, Basar R, Li Y, Daher M, Rafei H, Kerbauy LN, Kaplan M, Marin D, Griffin L, Barnett M, Bassett R, Uprety N, Shrestha R, Silva FR, Islam S, Ganesh C, Borneo Z, Ramdial J, Ramirez A, Hosing C, Alousi A, Popat U, Qazilbash M, Ahmed S, Iyer S, Sainz TP, Vega F, Fowlkes NW, Alexis K, Emig M, Harstrick A, Overesch A, Shpall EJ, Rezvani K. Allogeneic NK cells with a bispecific innate cell engager in refractory relapsed lymphoma: a phase 1 trial. Nat Med. e-Pub 2025. PMID: 40186077.
2. E S, Vega F, Khanlari M, Fang H, Xu J, Li S, Hu S, Wang SA, Wei Q, Wang WJ, Medeiros LJ, Wang W. BCL11B helps to define T-lineage in lymphomas/leukaemias with a mixed/ambiguous immunophenotype. Pathology, 2025. e-Pub 2025. PMID: 40318959.
3. Bosch-Schips J, Parisi X, Climent F, Vega F. Bridging Clinicopathologic Features and Genetics in Follicular Lymphoma: Towards Enhanced Diagnostic Accuracy and Subtype Differentiation. Hum Pathol 156, 2025. e-Pub 2025. PMID: 39490765.
4. Amador C, Weisenburger DD, Gomez A, Bouska A, Alshomrani A, Sharma S, Shah R, Greiner TC, Vega F, Rosenwald A, Ott G, Feldman AL, Jaffe ES, Ozkaya N, Ondrejka SL, Cook JR, Raess PW, Savage KJ, Slack GW, Song JY, Scott DW, Campo E, Rimsza LM, Khoury JD, Staudt LM, Chan WC, Iqbal J. Refining Diagnostic Subtypes of Peripheral T-cell Lymphoma Using a Multiparameter Approach. Mod Pathol 38(2), 2025. e-Pub 2024. PMID: 39491745.
5. Gaulin C, Jain P, Nair R, Iyer SP, Lee HJ, Fayad L, Feng L, Ok CY, Kanagal-Shamanna R, Oriabure O, Chen W, Xu G, Deswal A, Iliescu C, Badillo M, Ky M, Avellaneda M, Tangc G, Medeiros LJ, Vega F, Flowers CR, Wang ML. Phase 2 trial of ibrutinib in previously untreated high-risk smoldering mantle cell lymphoma. Leuk Lymphoma. e-Pub 2025. PMID: 39838574.
6. Nahmod KA, Miranda RN, Vega F, Thakral B, Pemmaraju N, Montalban-Bravo G, Loghavi S, Jelloul FZ, Wang W, Wang S, Muzzafar T, Patel K, Bueso-Ramos CE, Medeiros LJ, Kanagal-Shamanna R. Diagnostic challenges of high-grade myeloid malignancies with partial plasmacytoid dendritic cell differentiation: report of two cases with literature review. Leuk Lymphoma 66(4):764-772, 2025. e-Pub 2025. PMID: 39704386.
7. Segura-Rivera R, Dcunha NJ, Dimopoulos YP, Mundhada A, Sainz TP, Kettlun C, Sahu V, Sarami I, Miranda RN, Lin P, Medeiros LJ, Vega F. The Spectrum of B-cell and Plasma Cell Proliferations in Nodal T Follicular Helper Cell Lymphomas. Am J Surg Pathol 49(3):251-264, 2024. e-Pub 2024. PMID: 39618194.
8. Friedberg, JW, Brady, MT, Strawderman, M, Kahl, BS, Lossos, IS, Cohen, JB, Reagan, P, Casulo, C, Averill, B, Baran, A, Sutamtewagul, G, Barr, PM, Leonard, JP, Ashton, JM, Strang, JG, Vega, F, Peterson, DR, Nastoupil, L. Vitamin D in patients with low tumor-burden indolent non-Hodgkin lymphoma treated with rituximab therapy (ILyAD). EClinicalMedicine 78, 2024. e-Pub 2024. PMID: 39677358.
9. Morrow WP, Milligan NS, Ohgami RS, Young KH, Wang B, Vega F, Marques-Piubelli ML, Feldman AL, Slack GW, Savage KJ, Zhao X, Rubenstein JL, Hsi ED. Clinicopathologic features of primary central nervous system anaplastic large cell lymphoma: a multicenter study identifies age and ALK status as prognostic factors. J Hematop 17(4):215-222, 2024. e-Pub 2024. PMID: 39549220.
10. Friedberg JW, Brady MT, Strawderman M, Kahl BS, Lossos IS, Cohen JB, Reagan PM, Casulo C, Averill BL, Baran A, Sutamtewagul G, Barr PM, Leonard JP, Ashton JM, Strang JG, Vega F, Peterson DR, Nastoupil LJ. Vitamin D in patients with low tumor-burden indolent non-Hodgkin lymphoma treated with rituximab therapy (ILyAD): a randomized, phase 3 clinical trial. EClinicalMedicine, 2024. e-Pub 2024. PMID: 39677358.
11. Abro B, Maurer MJ, Habermann TM, Burack R, Chapman JR, Cohen JB, Friedberg JW, Inghirami GG, Kahl BS, Larson MC, Link BL, Lossos IS, Martin P, McDonnell T, Nastoupil LJ, Riska S, Syrbu SI, Vega F, Vij K, Flowers CR, Cerhan JR, Jaye DL, Feldman AL. Real-world impact of differences in the WHO and ICC classifications of non-Hodgkin lymphoma: a LEO Cohort Study analysis. Blood 144(19):2063-2066, 2024. e-Pub 2024. PMID: 39255410.
12. Gunawardana J, Law SC, Sabdia MB, É F, Hennessy A, Leahy CI, Murray PG, Bednarska K, Brosda S, Trotman J, Berkahn L, Zaharia A, Birch S, Burgess M, Talaulikar D, Lee JN, Jude E, Hawkes EA, Jain S, Nath K, Snell C, Swain F, Tobin JWD, Keane C, Shanavas M, Blyth E, Steidl C, Savage K, Farinha P, Boyle M, Meissner B, Green MR, Vega F, Gandhi MK. Intra-tumoral and peripheral blood TIGIT and PD-1 as immune biomarkers in nodular lymphocyte predominant Hodgkin lymphoma. Am J Hematol 99(11):2096-2107, 2024. e-Pub 2024. PMID: 39152767.
13. Sainz TP, Sahu V, Gomez JA, Dcunha NJ, Basi AV, Kettlun C, Sarami I, Burks JK, Sampath D, Vega F. Role of the crosstalk B:neoplastic T follicular helper (TFH) cells in the pathobiology of nodal TFH cell lymphomas. Lab Invest 104(11), 2024. e-Pub 2024. PMID: 39389311.
14. Acharya S, Basar R, Daher M, Rafei H, Li P, Uprety N, Ensley E, Shanley M, Kumar B, Banerjee PP, Melo Garcia L, Lin P, Mohanty V, Kim KH, Jiang X, Pan Y, Li Y, Liu B, Nunez Cortes AK, Zhang C, Fathi M, Rezvan A, Montalvo MJ, Cha SL, Reyes-Silva F, Shrestha R, Guo X, Kundu K, Biederstadt A, Muniz-Feliciano L, Deyter GM, Kaplan M, Jiang XR, Liu E, Jain A, Roszik J, Fowlkes NW, Solis Soto LM, Raso MG, Khoury JD, Lin P, Vega F, Varadarajan N, Chen K, Marin D, Shpall EJ, Rezvani K. CD28 costimulation augments CAR signaling in NK cells via the LCK/CD3Z/ZAP70 signaling axis. Cancer Discov 14(10):1879-1900, 2024. e-Pub 2024. PMID: 38900051.
15. Santos Louro L, Dimopoulos Y, Leventaki V, Vega F. Follicular lymphoma of the lower female genital tract: an indolent and localized extranodal follicular lymphoma with mutation of TNFRSF14. Leuk Lymphoma, 2024. e-Pub 2024. PMID: 39034476.
16. Wu SY, Damron EP, Xu J, Fang PQ, Dai J, Nair R, Malpica Castillo LE, Fayad LE, Torres-Cabala CA, Medeiros LJ, Vega F, Miranda RN, Duvic M, Pinnix CC, Dabaja BS, Iyer SP, Huen AO, Gunther JR. Radiotherapy in the treatment of primary cutaneous CD4+ small/medium T-cell lymphoproliferative disorder. Int J Dermatol 64(2):385-389, 2024. e-Pub 2024. PMID: 38955474.
17. Fang H, Wang SA, Beird HC, Tang Z, You MJ, Li S, Xu J, Hu S, Yin CC, El Hussein S, Lin P, Jelloul FZ, Vega F, Medeiros LJ, Wang W. Morphology, immunophenotype, and suggested diagnostic criteria of TCL1 family-negative T-prolymphocytic leukemia. Am J Clin Pathol, 2024. e-Pub 2024. PMID: 38946194.
18. Wang X, Wang W, Vega F, Quesada AE. Aggressive Mediastinal Lymphomas. Semin Diagn Pathol 41(21):125-139, 2024. e-Pub 2024. PMID: 34175178.
19. Binkley MS, Flerlage JE, Savage KJ, Akhtar S, Steiner R, Zhang XY, Dickinson M, Prica A, Major A, Hendrickson PG, Hopkins D, Ng A, Casulo C, Baron J, Roberts KB, Al Kendi J, Balogh A, Ricardi U, Torka P, Specht L, De Silva R, Pickard K, Blazin LJ, Henry M, Smith CM, Halperin D, Brady J, Brennan B, Senchenko MA, Reeves M, Hoppe BS, Terezakis S, Talaulikar D, Picardi M, Kirova Y, Fergusson P, Hawkes EA, Lee D, Doo NW, Barraclough A, Cheah CY, Ku M, Hamad N, Mutsando H, Gilbertson M, Marconi T, Viiala N, Maurer MJ, Eichenauer DA, Hoppe RT, Consortium G. International Prognostic Score for Nodular Lymphocyte-Predominant Hodgkin Lymphoma. J Clin Oncol 42(19):2271-2280, 2024. e-Pub 2024. PMID: 38531001.
20. Nze C, Andersen C, Ayers A, Westin JR, Wang ML, Iyer SP, Ahmed S, Pinnix CC, Vega F, Nguyen L, McNeill L, Nastoupil LJ, Zhang K, Bauer C, Flowers CR. Impact of Demographics and Neighborhood Socioeconomic Variables on Clinical Trial Participation in Non-Hodgkin Lymphoma. Blood Adv 8(14):3825-3837, 2024. e-Pub 2024. PMID: 38607394.
21. Gordon, MJ, Feng, L, Strati, P, Lee, HJ, Hagemeister, FB, Westin, JR, Samaniego, F, Marques-Piubelli, ML, Vega, F, Parra Cuentas, ER, Solis Soto, LM, Ma, W, Wang, J, Claret, LC, Averill, B, Ibanez, K, Fayad, LE, Flowers, CR, Green, M, Davis, RE, Neelapu, SS, Fowler, N, Nastoupil, L. Safety and efficacy of ibrutinib in combination with rituximab and lenalidomide in previously untreated follicular and marginal zone lymphoma. Cancer 130(6):876-885, 2024. e-Pub 2024. PMID: 37985359.
22. Vega F, Lakra P, Gou P, Yang H, Meydan C, Teater M, Chin C, Zhang W, Dinh T, Hussein U, Li X, Rojas E, Liu W, Reville PK, Kizhakeyil A, Barisic D, Parsons S, Wilson A, Henderson J, Scull B, Gurumurthy C, Vega F, Chadburn A, Cuglievan B, El-Mallawany NK, Allen C, Mason C, Melnick A, Green MR. SMARCA4 is a haploinsufficient B cell lymphoma tumor suppressor that fine-tunes centrocyte cell fate decisions. Cancer cell 42(4):605-622.e11, 2024. e-Pub 2024. PMID: 38458188.
23. Siddiqui S, Jain P, Wang M, Thakral B, Li S, Miranda R, Vega F, Medeiros LJ, Ok CY. TP53 mutation is frequent in mantle cell lymphoma with EZH2 expression and have dismal outcome when both are present. Human Pathology 146:1-7, 2024. e-Pub 2024. PMID: 38460798.
24. Marques Piubelli-M, Kumar B, Basar R, Panowski S, Srinivasan S, Norwood K, Prashad S, Szenes V, Balakumaran A, Arandhya A, Lu W, Khan K, Duenas D, McAllen S, Gomez JA, Burks JK, Acharyal S, Borthakur G, Wang WL, Wang W, Wang S, Solis LM, Marin D, Rezvani K, Daher M, Vega F. Increased expression of CD70 in relapsed acute myeloid leukemia after hypomethylating agents. Virchows Arch 485(5):937-941, 2024. e-Pub 2024. PMID: 38388965.
25. Cerhan JR, Maurer MJ, Link BK, Feldman AL, Habermann TM, Jaye DL, Burack WR, McDonnell TJ, Vega F, Chapman JR, Syrbu S, Vij KR, Inghirami G, Leonard JP, Bernal-Mizrachi L, Farooq U, Witzig TE, Weiner GJ, Wang Y, Alderuccio JP, Slager SL, Larson MC, Riska SM, Gysbers BJ, Lunde JJ, Reicks TW, Ayers AA, O'Leary CB, Yost KJ, Liu H, Nowakowski GS, Ruan J, Chihara D, Koff JL, Casulo C, Thompson CA, Cohen JB, Kahl BS, Nastoupil LJ, Lossos IS, Friedberg JW, Martin P, Flowers CR. The Lymphoma Epidemiology of Outcomes cohort study. American journal of hematology 99(3):408-421, 2024. e-Pub 2024. PMID: 38217361.
26. Chu F, Liu J, Davis TJ, Cheng X,, Karri S, Bover L, Vega F, Green M. Chimeric antigen receptor T cells to target CD79b in B-cell lymphomas. Journal for immunotherapy of cancer 11(11), 2023. e-Pub 2023. PMID: 38007239.
27. Steiner RE, Hwang SR, Khurana A, Habermann TM, Epperla N, Annunzio K, Allen PB, Baird K, Paulino D, Alderuccio JP, Lossos IS, David KA, Evens AM, Pandya K, Bair SM, Kamdar M, Ba Aqeel SH, Torka P, Lynch RC, Smith SD, Feng L, Noorani M, Ahmed S, Nair R, Vega F, Wu S, Fang PQ, Pinnix CC, Gunther JR, Dabaja BS, Lee HJ. Impact of Cumulative Dose of Brentuximab Vedotin on Outcomes of Frontline Therapy for Advanced Stage Hodgkin Lymphoma. Blood Adv 7(24):7485-7493, 2023. e-Pub 2023. PMID: 37603594.
28. Strati P, Li X, Deng Q, Marques-Piubelli ML, Henderson J, Watson G, Deaton L, Cain T, Yang H, Ravanmehr V, Fayad LE, Iyer SP, Nastoupil LJ, Hagemeister FB, Parra ER, Saini N, Takahashi K, Fowler NH, Westin JR, Steiner RE, Nair R, Flowers CR, Wang L, Ahmed S, Al-Atrash G, Vega F, Neelapu SS, Green MR. Prolonged cytopenia following CD19 CAR T cell therapy is linked with bone marrow infiltration of clonally expanded IFNγ-expressing CD8 T cells. Cell Rep Med 15(4), 2023. e-Pub 2023. PMID: 37586321.
29. Marques-Piubelli ML, Kim DH, Medeiros LJ, Lu W, Khan K, Gomez-Bolanos LI, Rodriguez S, Parra ER, Ok CY, Aradhya A, Solis LM, Nieto YL, Steiner R, Ahmed S, Vega F. CD30 expression is frequently decreased in relapsed classic Hodgkin lymphoma after anti-CD30 CAR T-cell therapy. Histopathology 83(1):143-148, 2023. e-Pub 2023. PMID: 36994939.
30. Qiu L, Tang G, Li S, Vega F, Lin P, Wang SA, Wang W, Iyer SP, Malpica L, Miranda RN, Konoplev S, Tang Z, Fang H, Medeiros LJ, Xu J. DUSP22 rearrangement is associated with distinctive immunophenotype but not outcome in patients with systemic ALK-negative anaplastic large cell lymphoma. Haematologica 108(6):1604-1615, 2023. e-Pub 2022. PMID: 36453104.
31. Khanlari M, Mo H, Kim DH, Sakhdari A, Young KH, Jain P, Wang M, Li S, Kanagal-Shamanna R, Miranda RN, Vega F, Medeiros LJ, Ok CY. Blastoid and Pleomorphic Mantle Cell Lymphoma Demonstrate Distinct Clinicopathologic and Genetic Features. Am J Surg Pathol 47(8):849-858, 2023. e-Pub 2023. PMID: 37288826.
32. Aguilar C, Beltran BE, Morales D, Gutiérrez-Garibay M, Villela L, Marques-Piubelli ML, Vega F, Miranda RN, Malpica L. Isolated cardiac valve involvement in smoldering adult T-cell leukemia/lymphoma. Cardiovasc Pathol 64:107513, 2023. e-Pub 2022. PMID: 36567046.
33. Mas G, Man N, Nakata Y, Martinez-Caja C, Karl DL, Beckedorff F, Tamiro F, Chen C, Duffort S, Itonaga H, Mookhtiar AK, Kunkalla K, Valencia AM, Collings CK, Kadoch C, Vega F, Kogan SC, Morey L, Bilbao D, Nimer SD. The SWI/SNF chromatin remodeling subunit DPF2 facilitates NRF2-dependent anti-inflammatory and anti-oxidant gene expression. J Clin Invest 133(13), 2023. e-Pub 2023. PMID: 37200093.
34. Tang G, Li S, Toruner GA, Jain P, Tang Z, Hu S, Xu J, Cheng J, Robinson M, Vega F, Medeiros LJ. Clinical impact of 5'MYC or 3'MYC gain/loss detected by FISH in patients with aggressive B-cell lymphomas. Cancer Genet 272-273:1-8, 2023. e-Pub 2022. PMID: 36566629.
35. Steiner RE, Parra ER, Vega F, Feng L, Westin JR, Neelapu SS, Strati P, Green MR, Flowers CR, Solis LM, Wistuba II, Ahmed S, Nair R, Hagemeister FB, Noorani M, Marques-Piubelli ML. PD-L1+ macrophages are associated with favorable features in primary mediastinal (thymic) large B-cell lymphoma. Exp Hematol Oncol 12(1):32, 2023. e-Pub 2023. PMID: 36941707.
36. Marques-Piubelli ML, Amador C, Vega F. Pathologic and molecular insights in nodal T-follicular helper cell lymphomas. Front Oncol 13, 2023. e-Pub 2023. PMID: 36793612.
37. Nahmod KA, Vega F. ALK-positive large B-cell lymphoma, a rare B-cell lymphoma expressing ALK. Blood 141(2):209, 2023. e-Pub 2023. PMID: 36633881.
38. Qiu L, Xu J, Lin P, Cohen EN, Tang G, Wang SA, Khanlari M, Wang W, Khoury JD, Konoplev S, Yin CC, Jorgensen JL, Vega F, Medeiros LJ, Li S. Unique pathologic features and gene expression signatures distinguish blastoid high-grade B-cell lymphoma from B acute lymphoblastic leukemia/lymphoma. Haematologica 108(3):895-899, 2022. e-Pub 2022. PMID: 36325892.
39. Cherng HJ, Alig S, Oki Y, Nastoupil LJ, Fayad LE, Neelapu SS, Turturro F, Hagemeister FB, Craig A, Macaulay C, Rodriguez MA, Lee HJJ, McDonnell T, Flowers CR, Vega F, Green MR, Feng L, Kurtz DM, Alizadeh AA, Davis RE, Westin JR. A phase 1/2 study of lenalidomide and obinutuzumab with CHOP for newly diagnosed DLBCL. Blood Adv 7(7):1137-1145, 2022. e-Pub 2022. PMID: 36375046.
40. Nair R, Oki Y, Fowler N, Wang M, Ma MCJ, Vega F, McDonnell T, Pinnix C, Griffith D, Lu Y, Tewari S, Sun R, Scott DW, Flowers CR, Neelapu S, Green MR. Smart Start: Rituximab, Lenalidomide, and Ibrutinib in Patients With Newly Diagnosed Large B-Cell Lymphoma. J Clin Oncol 41(4):745-755, 2022. e-Pub 2022. PMID: 35952327.
41. Brown DN, Blessing MM, Marcogliese AN, Vega F, Prose N, Metry D. Childhood lymphomatoid papulosis Type D, a rare and challenging diagnosis. Pediatr Dermatol 39(6):943-945, 2022. e-Pub 2022. PMID: 35817594.
42. Fang H, Khoury JD, Torres-Cabala CA, Ng SB, Xu J, El Hussein S, Hu S, Vega F, Li S, Tang Z, Tang G, Medeiros LJ, Wang W. Expression pattern and diagnostic utility of BCL11B in mature T- and NK-cell neoplasms. Pathology 54(7):893-899, 2022. e-Pub 2022. PMID: 35864006.
43. Romain G, Strati P, Rezvan A, Fathi M, Bandey IN, Adolacion JR, Heeke DS, Liadi I, Marques-Piubelli ML, Solis Soto LM, Mahendra A, Vega F, Cooper LJ, Singh H, Mattie M, Bot A, Neelapu S, Varadarajan N. Multidimensional single-cell analysis identifies a role for CD2-CD58 interactions in clinical antitumor T cell responses. J Clin Inves 132(17), 2022. e-Pub 2022. PMID: 35881486.
44. Alaggio, R, Amador, C, Anagnostopoulos, I, Attygalle, AD, de Oliveira Araujo, IB, Berti, E, Bhagat, G, Borges, AM, Boyer, DF, Calaminici, M, Chadburn, A, Chan, JK, Cheuk, W, Chng, WJ, Choi, JK, Chuang, SS, Coupland, SE, Czader, M, Dave, SS, De Jong, D, DiNapoli, A, Du, MQ, Elenitoba-Johnson, KS, Ferry, JA, Geyer, JT, Gratzinger, D, Guitart, J, Gujral, S, Harris, MH, Harrison, CJ, Hartmann, S, Hochhaus, A, Jansen, PM, Karube, K, Kempf, W, Khoury, J, Kimura, H, Klapper, W, Kovach, AE, Kumar, SK, Lazar, A, Lazzi, S, Leoncini, L, Leung, N, Leventaki, V, Medeiros, LJ, Miranda, R, Vega, F, Burger, JA, Jain, N. The 5th edition of The World Health Organization Classification of Haematolymphoid Tumours: Lymphoid Neoplasms”. Leukemia 36(7):1720-1748, 2022. e-Pub 2022. PMID: 37468552.
45. Ghosh A, Marques-Piubelli ML, Wang X, Sheu TG, Cheng J, Khan K, Lu W, Manning J, Tang G, Solis LM, Vega F. CD2-negative lymphoma-associated T-cells: a potential mechanism of immune-evasion in diffuse large B-cell lymphoma. Virchows Arch 481(4):659-663, 2022. e-Pub 2022. PMID: 35622145.
46. Chioureas D, Beck J, Baltatzis G, Vardaki I, Fonseca P, Tsesmetzis N, Vega F, Leventaki V, Eliopoulos AG, Drakos E, Rassidakis GZ, Panaretakis T. ALK+ Anaplastic Large Cell Lymphoma (ALCL)-Derived Exosomes Carry ALK Signaling Proteins and Interact with Tumor Microenvironment. Cancers (Basel) 14(12), 2022. e-Pub 2022. PMID: 35740600.
47. Gouni S, Strati P, Toruner G, Aradhya A, Landgraf R, Bilbao D, Vega F, Agarwal NK. Statins enhance the chemosensitivity of R-CHOP in diffuse large B-cell lymphoma. Leuk Lymphoma 63(6):1302-1313, 2022. e-Pub 2022. PMID: 34969327.
48. Marques-Piubelli ML, Parra Cuentas ER, Feng L, Solis Soto L, Gallardo M, Gouni S, Samaniego F, Noorani M, Hagemeister FB, Westin JR, Lee HJ, Rodriguez MA, Neelapu SS, Gunther JR, Fowler NH, Flowers CR, Wistuba II, Nastoupil LJ, Vega F, Strati P. SIRPα+ macrophages are increased in patients with FL who progress or relapse after frontline lenalidomide and rituximab. Blood Adv 6(11):3286-3293, 2022. e-Pub 2022. PMID: 35359004.
49. Han G, Deng Q, Marques-Piubelli ML, Dai E, Dang M, Ma MCJ, Li X, Yang H, Henderson J, Kudryashova O, Meerson M, Isaev S, Kotlov N, Nomie KJ, Bagaev A, Parra ER, Solis Soto LM, Parmar S, Hagemeister FB, Ahmed S, Iyer SP, Samaniego F, Steiner R, Fayad L, Lee H, Fowler NH, Flowers CR, Strati P, Westin JR, Neelapu SS, Nastoupil LJ, Vega F, Wang L, Green MR. Follicular lymphoma microenvironment characteristics associated with tumor cell mutations and MHC class II expression. Blood Cancer Discov, 2022. e-Pub 2022. PMID: 35687817.
50. Qiu L, Cho JH, Jelloul FZ, Vega F. SOHO State of the Art Updates and Next Questions: Pathology and Pathogenesis of Nodal Peripheral T-Cell Lymphomas. Clin Lymphoma Myeloma Leuk 22(5):287-296, 2022. e-Pub 2022. PMID: 34776400.
51. El Hussein S, Wang X, Fang H, Jelloul FZ, Wang W, Loghavi S, Vega F, Miranda RN, Muzzafar T, Manning JT, Khoury JD, Burack WR, Evans AG, Medeiros LJ. Nodular Lymphocyte-predominant Hodgkin Lymphoma With Nodular Sclerosis: An Underrecognized Feature Associated With Pattern D. Am J Surg Pathol 46(9):1291-1297, 2022. e-Pub 2022. PMID: 35575765.
52. Marques-Piubelli ML, Sagert J, Pham MT, Will M, Henderson D, Tipton K, Iyer S, Lu W, Khan KB, Hamana L, Chapman JR, Thakral B, Xu J, Miranda RN, Jennings K, Solis LM, Vega F. CD70 is a Potential Target Biomarker in Peripheral T-cell Lymphomas. Histopathology 81(2):272-275, 2022. e-Pub 2022. PMID: 35474464.
53. Agarwal NK, Kim CH, Kunkalla K, Vaghefi A, Sanchez S, Manuel S, Bilbao D, Vega F, Landgraf R. Smoothened (SMO) regulates insulin-like growth factor 1 receptor (IGF1R) levels and protein kinase B (AKT) localization and signaling. Lab Invest 102(4):401-410, 2022. e-Pub 2022. PMID: 34893758.
54. Qiu L, Wang SA, Vega F, Khoury JD, Tang Z, Garces S, Medeiros LJ, Thakral B. From the archives of MD Anderson Cancer Center: Intravascular large B-cell lymphoma with numerous circulating lymphoma cells. Ann Diagn Pathol 58:151934, 2022. e-Pub 2022. PMID: 35299081.
55. Wang ML, Jain P, Zhao S, Lee HJ, Nastoupil L, Fayad L, Ok CY, Kanagal-Shamanna R, Hill HA, Yao Y, Hagemeister FB, Westin JR, Fowler N, Samaniego F, Steiner R, Nair R, Iyer SP, Navsaria L, Badillo M, Research Group MC, Feng L, Xuelin H, Nogueras Gonzalez GM, Xu G, Wagner-Bartak N, Thirumurthi S, Santos D, Tang G, Lin P, Wang SA, Jorgensen J, Yin CC, Li S, Patel KP, Vega F, Medeiros LJ, Flowers CR, Wang L. Ibrutinib-rituximab followed by R-HCVAD as frontline treatment for young patients with mantle cell lymphoma (WINDOW-1): a single-arm, phase 2 trial. Lancet Oncol 23(3):406-415, 2022. e-Pub 2022. PMID: 35074072.
56. Vega F, Amador C, Chadburn A, Hsi ED, Slack G, Medeiros LJ, Feldman AL. Genetic profiling and biomarkers in peripheral T-cell lymphomas: current role in the diagnostic work-up. Mod Pathol 35(3):306-318, 2022. e-Pub 2022. PMID: 34584212.
57. Khanlari M, Li S, Miranda RN, Iyer S, Konoplev S, Lin P, Yin CC, Tang G, Qiu L, Vega F, Medeiros LJ, Xu J. Small cell/lymphohistiocytic morphology is associated with peripheral blood involvement, CD8 positivity and retained T-cell antigens, but not outcome in adults with ALK+ anaplastic large cell lymphoma. Mod Pathol 35(3):412-418, 2022. e-Pub 2022. PMID: 34628481.
58. Latchmansingh KA, Wang X, Verdun RE, Marques-Piubelli ML, Vega F, You MJ, Chapman J, Lossos IS. LMO2 expression is frequent in T-lymphoblastic leukemia and correlates with survival, regardless of T-cell stage. Mod Pathol 35(9):1220-1226, 2022. e-Pub 2022. PMID: 35322192.
59. Kim DH, Vega F. Relapsed classic Hodgkin lymphoma with decreased CD30 expression after brentuximab and anti-CD30 CAR-T therapies. Blood 139(6):951, 2022. e-Pub 2022. PMID: 35142847.
60. Jain P, Zhao S, Lee HJ, Hill HA, Ok CY, Kanagal-Shamanna R, Hagemeister FB, Fowler N, Fayad L, Yao Y, Liu Y, Moghrabi OB, Navsaria L, Feng L, Nogueras Gonzalez GM, Xu G, Thirumurthi S, Santos D, Iliescu C, Tang G, Medeiros LJ, Vega F, Avellaneda M, Badillo M, Flowers CR, Wang L, Wang ML. Ibrutinib With Rituximab in First-Line Treatment of Older Patients With Mantle Cell Lymphoma. J Clin Oncol 40(2):JCO2101797, 2022. e-Pub 2022. PMID: 34797699.
61. Qiu L, Xu J, Tang G, Wang SA, Lin P, Ok CY, Garces S, Yin CC, Khanlari M, Vega F, Medeiros LJ, Li S. Mantle Cell Lymphoma with Chronic Lymphocytic Leukemia-Like Features: A Diagnostic Mimic and Pitfall. Hum Pathol 119:59-68, 2022. e-Pub 2022. PMID: 34767860.
62. Wang ML, Jain P, Zhao S, Lee HJ, Nastoupil L, Fayad L, Ok CY, Kanagal-Shamanna R, Hill HA, Yao Y, Hagemeister FB, Westin JR, Fowler N, Samaniego F, Steiner R, Nair R, Iyer SP, Navsaria L, Research Group BMMC, Feng L, Xuelin H, Nogueras Gonzalez GM, Xu G, Wagner-Bartak N, Thirumurthi S, Santos D, Tang G, Lin P, Wang SA, Jorgensen J, Yin CC, Li S, Patel KP, Vega F, Medeiros LJ, Flowers CR, Wang L. Ibrutinib-rituximab followed by R-HCVAD as frontline treatment for young patients (≤65 years) with mantle cell lymphoma (WINDOW-1): a single-arm, phase 2 trial. Lancet Oncol:S1470-2045, 2022. e-Pub 2022. PMID: 35074702.
63. Medeiros LJ, Marques-Piubelli ML, Sangiorgio VFI, Ruiz-Cordero R, Vega F, Feldman AL, Chapman JR, Clemens MW, Hunt KK, Evans MG, Khoo C, Lade S, Silberman M, Morkowski J, Pina EM, Mills DC, Bates CM, Magno WB, Sohani AR, Sieling BA, O'Donoghue JM, Bacon CM, Patani N, Televantou D, Turner SD, Johnson L, MacNeill F, Wotherspoon AC, Iyer SP, Malpica LE, Patel KP, Xu J, Miranda RN. Epstein-Barr-virus-positive large B-cell lymphoma associated with breast implants: an analysis of eight patients suggesting a possible pathogenetic relationship. Mod Pathol 34(12):2154-2167, 2021. e-Pub 2021. PMID: 34226673.
64. Tashakori M, Kim DH, Kanagal-Shamanna R, Vega F, Miranda RN, Jain P, Wang M, Medeiros LJ, Ok CY. Mantle Cell Lymphoma Involving Tonsils: A Clinicopathologic Study of 83 Cases. Hum Pathol 118:60-68, 2021. e-Pub 2021. PMID: 34655612.
65. Steiner RE, Banchs J, Koutroumpakis E, Becnel M, Gutierrez C, Strati P, Pinnix CC, Feng L, Rondon G, Claussen C, Palaskas N, Karimzad K, Ahmed S, Neelapu SS, Shpall E, Wang M, Vega F, Westin J, Nastoupil LJ, Deswal A. Cardiovascular events in patients treated with chimeric antigen receptor t-cell therapy for aggressive B-cell lymphoma. Haematologica 107(7):1555-1566, 2021. e-Pub 2021. PMID: 34758610.
66. Magistri M, Happ LE, Ramdial J, Lu X, Stathias V, Kunkalla K, Agarwal N, Jiang X, Schürer SC, Dubovy SR, Chapman JR, Vega F, Dave S, Lossos IS. The Genetic Landscape of Ocular Adnexa MALT Lymphoma Reveals Frequent Aberrations in NFAT and MEF2B Signaling Pathways. Cancer Res Commun 1(1):1-16, 2021. e-Pub 2021. PMID: 35528192.
67. Magistri, M, Happ, LE, Ramdial, JL, Lu, X, Stathias, V, Kunkalla, K, Agarwal, N, Jiang, XY, Schürer, S, Dubovy, SR, Chapman, JR, Vega Vazquez, F, Dave, SS, Lossos, IS. The Genetic Landscape of Ocular Adnexa MALT Lymphoma Reveals Frequent Aberrations in NFAT and MEF2B Signaling Pathways. Cancer Research Communications 1(1):1-16, 2021. e-Pub 2021. PMID: 35528192.
68. Chapman JR, Bouska AC, Zhang W, Alderuccio JP, Lossos IS, Rimsza LM, Maguire A, Yi S, Chan WC, Vega F, Song JY. EBV-positive HIV-associated diffuse large B cell lymphomas are characterized by JAK/STAT (STAT3) pathway mutations and unique clinicopathologic features. Br J Haematol 194(5):870-878, 2021. e-Pub 2021. PMID: 34272731.
69. Marques-Piubelli ML, Solis LM, Parra ER, Castillo LM, Gouni S, Nair R, Chihara D, Konopleva M, Wistuba II, Iyer SP, Vega F, Strati P. BCL-W expression associates with poor outcome in patients with peripheral T-cell lymphoma not otherwise specified. Blood Cancer J 11(9):153, 2021. e-Pub 2021. PMID: 34531377.
70. Plaks V, Rossi JM, Chou J, Wang L, Poddar S, Han G, Wang Z, Kuang SQ, Chu F, Davis RE, Vega F, Bashir Z, Jacobson CA, Locke FL, Reagan PM, Rodig SJ, Lekakis LJ, Flinn IW, Miklos DB, Bot A, Neelapu SS. CD19 target evasion as a mechanism of relapse in large B-cell lymphoma treated with axicabtagene ciloleucel. Blood 138(12):1081-1085, 2021. e-Pub 2021. PMID: 34041526.
71. Martinez-Baquero D, Sakhdari A, Mo H, Kim DH, Kanagal-Shamanna R, Li S, Young KH, O'Malley DP, Dogan A, Jain P, Wang ML, McDonnell TJ, Miranda RN, Vega F, Medeiros LJ, Ok CY. EZH2 expression is associated with inferior overall survival in mantle cell lymphoma. Mod Pathol 34(12):2183-2191, 2021. e-Pub 2021. PMID: 34376807.
72. Collins K, Gu J, Aung PP, Nagarajan P, Curry JL, Huen A, Ivan D, Prieto VG, Tetzlaff MT, Duvic M, Miranda RN, Vega F, Torres-Cabala CA. Is immunohistochemical expression of GATA3 helpful in the differential diagnosis of transformed mycosis fungoides and primary cutaneous CD30-positive T cell lymphoproliferative disorders?. Virchows Arch 479(2):377-383, 2021. e-Pub 2021. PMID: 33604757.
73. Thakral B, Jain N, Tang G, Konoplev S, Vega F, Medeiros LJ, Wang SA. From the archives of MD Anderson Cancer Center: Concurrent BCR-ABL1 and CRLF2 rearrangements in B-lymphoblast phase of chronic myeloid leukemia. Ann Diagn Pathol 53:151767, 2021. e-Pub 2021. PMID: 34118580.
74. Diaz-Perez JA, Poveda JC, Chapman JR, Velez-Torres JM, Vega F, Rosenberg AE. Unexpected Primary Extranodal Marginal Zone Lymphoma of Bone in Amputation and Arthroplasty Specimens. Am J Clin Pathol 156(6):1038-1043, 2021. e-Pub 2021. PMID: 34075398.
75. Oishi N, Hundal T, Phillips JL, Dasari S, Hu G, Viswanatha DS, He R, Mai M, Jacobs HK, Ahmed NH, Syrbu SI, Salama Y, Chapman JR, Vega F, Sidhu J, Bennani NN, Epstein AL, Medeiros JL, Clemens MW, Miranda RN, Feldman AL. Molecular profiling reveals a hypoxia signature in breast implant-associated anaplastic large cell lymphoma. Haematologica 106(6):1714-1724, 2021. e-Pub 2021. PMID: 32414854.
76. Marques-Piubelli ML, Schlette EJ, Khoury JD, Furqan F, Vega F, Soto LMS, Wistuba II, Wierda WG, Konopleva M, Ferrajoli A, Strati P. Expression of BCL2 alternative proteins and association with outcome in CLL patients treated with venetoclax. Leuk Lymphoma 62(5):1129-1135, 2021. e-Pub 2021. PMID: 33327833.
77. Jain P, Kanagal-Shamanna R, Zhang S, Ok CY, Navsaria L, Nastoupil L, Lee HJ, Tang G, Yin CC, Badillo M, Nair R, Li S, Patel KM, Flowers C, Vega F, Wang L, Wang ML. Outcomes of relapsed mantle cell lymphoma patients after discontinuing acalabrutinib. Am J Hematol 96(5):E137-E140, 2021. e-Pub 2021. PMID: 33491779.
78. Qiu L, Weitzman SP, Nastoupil LJ, Williams MD, Medeiros LJ, Vega F. Disseminated ALK-positive histiocytosis with KIF5B-ALK fusion in an adult. Leuk Lymphoma 62(5):1234-1238, 2021. e-Pub 2021. PMID: 33353436.
79. Poveda J, Cassidy DP, Zhou Y, Alderuccio JP, Lossos IS, Vega F, Chapman J. Expression of germinal center cell markers by extranodal marginal zone lymphomas of MALT type within colonized follicles, a diagnostic pitfall with follicular lymphoma. Leuk Lymphoma 62(5):1116-1122, 2021. e-Pub 2021. PMID: 33283568.
80. Sweeney KJ, Tetzlaff MT, Vega F, Gillenwater A, Zuo Z, Gross N, Nagarajan P, Wargo J, Nelson K, Prieto VG, Torres-Cabala CA, Curry JL. Tertiary lymphoid structures with overlapping histopathologic features of cutaneous marginal zone lymphoma during neoadjuvant cemiplimab therapy are associated with antitumor response. J Cutan Pathol 48(5):674-679, 2021. e-Pub 2021. PMID: 33399228.
81. Chihara D, Miljkovic M, Iyer SP, Vega F. Targeted based therapy in nodal T-cell lymphomas. Leukemia 35(4):956-967, 2021. e-Pub 2021. PMID: 33664464.
82. Lyapichev KA, Bah I, Huen A, Duvic M, Routbort MJ, Wang W, Jorgensen JL, Medeiros LJ, Vega F, Craig FE, Wang SA. Determination of immunophenotypic aberrancies provides better assessment of peripheral blood involvement by mycosis fungoides/Sézary syndrome than quantification of CD26- or CD7- CD4+ T-cells. Cytometry B Clin Cytom 100(2):183-191, 2021. e-Pub 2021. PMID: 32667737.
83. Arumov A, Liyanage PY, Trabolsi A, Roberts ER, Li L, BCLB F, Gao Z, Ban Y, Newsam AD, Taggart MW, Vega F, Bilbao D, Leblanc RM, Schatz JH. Optimized doxorubicin chemotherapy for diffuse Large B-Cell lymphoma exploits nanocarrier delivery to transferrin receptors. Cancer Res 81(3):763-775, 2021. e-Pub 2021. PMID: 33177062.
84. Lyapichev KA, Tang G, Li S, You MJ, Cheng TJ, Miranda RN, Iyer S, Yin CC, Konoplev S, Bueso-Ramos C, Vega F, Medeiros LJ, Xu J. MYC expression is associated with older age, common morphology, increased MYC copy number, and poorer prognosis in patients with ALK+ anaplastic large cell lymphoma. Hum Pathol 108:22-31, 2021. e-Pub 2021. PMID: 33221344.
85. Khanlari M, Tang G, Hao S, Gong Y, Li S, Miranda RN, Lin P, Iyer S, Yin CC, Xie W, Vega F, Medeiros LJ, Xu J. Anaplastic lymphoma kinase (ALK)-negative anaplastic large cell lymphoma with MYC rearrangement. Br J Haematol 192(1):e17-e21, 2021. e-Pub 2021. PMID: 33216956.
86. Tran J, Vega F, Duvic M. Unmasking a T cell lymphoma: Folliculotropic mycosis fungoides with a gamma-delta phenotype. JAAD Case Rep 6(12):1316-1319, 2020. e-Pub 2020. PMID: 32989422.
87. Vega F, Amador C, Chadburn A, Feldman AL, Hsi ED, Wang W, Medeiros LJ. American Registry of Pathology Expert Opinions: Recommendations for the diagnostic workup of mature T cell neoplasms. Ann Diagn Pathol 49:151623, 2020. e-Pub 2020. PMID: 32947231.
88. El Hussein S, Shaw KRM, Vega F. Evolving insights into the genomic complexity and immune landscape of diffuse large B-cell lymphoma: opportunities for novel biomarkers. Mod Pathol 33(12):2422-2436, 2020. e-Pub 2020. PMID: 32620919.
89. Lyapichev KA, You MJ, Vega F, Solis LM, Medeiros LJ. Classic Hodgkin lymphoma and Castleman disease: an entity appears to be emerging. Virchows Arch 477(33):437-444, 2020. e-Pub 2020. PMID: 32152665.
90. Vega F. Pathology and Pathogenesis of T-Cell Lymphoma. Clin Lymphoma Myeloma Leuk 20(Suppl 1):S89-S93, 2020. e-Pub 2020. PMID: 32862884.
91. Vega F, Medeiros LJ. A Suggested Immunohistochemical Algorithm for the Classification of T Cell Lymphomas Involving Lymph Node. Hum Pathol 102:104-116, 2020. e-Pub 2020. PMID: 32479842.
92. Safavi S, Larouche A, Zahn A, Patenaude AM, Domanska D, Dionne K, Rognes T, Dingler F, Kang SK, Johnson N, Hebert J, Verdun RE, Rada CA, Vega F, Nilsen H, Di Noia JM. The uracil-DNA glycosylase UNG protects the fitness of normal and cancer B cells expressing AID. Nuclei Acids Research Cancer 2(3):zcaa019, 2020. e-Pub 2020. PMID: 33554121.
93. Husnain M, Kuker R, Reis IM, Iyer SG, Zhao W, Chapman JR, Vega F, Lossos IS, Alderuccio JP. Clinical and radiological characteristics of patients with pulmonary marginal zone lymphoma: A single center analysis. Cancer Med 9(14):5051-5064, 2020. e-Pub 2020. PMID: 32452658.
94. Zhao S, Kanagal-Shamanna R, Navsaria L, Ok CY, Zhang S, Nomie K, Han G, Hao D, Hill HA, Jiang C, Yao Y, Nastoupil L, Westin J, Fayad L, Nair R, Steiner R, Ahmed S, Samaniego F, Iyer SP, Oriabure O, Chen W, Song X, Zhang J, Badillo M, Moghrabi O, Aranda J, Tang G, Yin CC, Patel K, Medeiros LJ, Li S, Vega F, Thirumurthi S, Xu G, Neelapu S, Flowers CR, Romaguera J, Fowler N, Wang L, Wang ML, Jain P. Efficacy of venetoclax in high risk relapsed mantle cell lymphoma (MCL) - outcomes and mutation profile from venetoclax resistant MCL patients. Am J Hematol 95(6):623-629, 2020. e-Pub 2020. PMID: 32239765.
95. Fayne R, Rengifo SS, Gonzalez I, Solorzano JL, Gonzalez D, Vega F, Cho-Vega JH. Primary cutaneous Rosai-Dorfman disease; a case-based review of a diagnostically and therapeutically challenging rare variant. Ann Diagn Pathol 45:151446, 2020. e-Pub 2020. PMID: 31978810.
96. Alderuccio JP, Isrow D, Reis IM, Iyer SG, Meshman JJ, Zhao W, Vega F, Chapman JR, Markoe AM, Lossos IS. Diagnostic bone marrow biopsy in patients with stage I EMZL treated with radiation therapy: needed or not?. Blood 135(15):1299-1302, 2020. e-Pub 2020. PMID: 31978219.
97. Chapman JR, Alvarez JP, White K, Sanchez S, Khanlari M, Algashaamy K, Cassidy D, Peng JH, Fan YS, Alencar A, Alderuccio JP, Lossos IS, Vega F. Unusual variants of follicular lymphoma: case-based review. Am J Surg Pathol 44(3):329-339, 2020. e-Pub 2020. PMID: 31688142.
98. Cassidy DP, Chapman JR, Lopez R, White K, Fan YS, Casas C, Severson EA, Vega F. Comparison Between Integrated Genomic DNA/RNA Profiling and Fluorescence In Situ Hybridization in the Detection of MYC, BCL-2, and BCL-6 Gene Rearrangements in Large B-Cell Lymphomas. Am J Clin Pathol 153(3):353-359, 2020. e-Pub 2020. PMID: 31872861.
99. Guo F, Luo Y, Jiang X, Lu X, Roberti D, Lossos C, Kunkalla K, Magistri M, Rui L, Verdun R, Vega F, Moy VT, Lossos IS. Recent BCR stimulation induces a negative auto-regulatory loop via FBXO10 mediated degradation of HGAL. Leukemia 34(2):553-566, 2020. e-Pub 2020. PMID: 31570756.
100. Vega F, Miranda RN, Medeiros LJ. KSHV/HHV8 Positive Large B-Cell Lymphomas and Associated Diseases: A Heterogeneous Group of Lymphoproliferative Processes with Significant Clinicopathological Overlap. Mod Pathol 33(1):18-28, 2020. e-Pub 2020. PMID: 31527708.
101. Marques-Piubelli ML, Salas YI, Pachas C, Becker-Hecker R, Vega F, Miranda RN. Epstein-Barr virus-associated B-cell lymphoproliferative disorders and lymphomas: a review. Pathology 52(1):40-52, 2020. e-Pub 2020. PMID: 31706670.
102. Gallastegui N, Cassidy DP, Heros DO, Vega F, Schatz JH. Central Nervous System Involvement by Small Lymphocytic Lymphoma after a Myxoma-Related Embolic Event. Case Rep Hematol 2019:1825491, 2019. e-Pub 2019. PMID: 31827948.
103. Fayne R, Rosenberg M, Whi9te K, Alencar A, Kirsner RS, Vega F, Cho-Vega JH. Disseminated cutaneous immunoglobulin M macroglobulinosis associated with cryoglobulinemia and minimal residual disease of Waldenstrom macroglobulinemia. JAAD Case Rep 5(10):918-922, 2019. e-Pub 2019. PMID: 31646164.
104. Parvin S, Labrada AR, Aumann S, Lu XQ, Weich N, Santiago GE, Cortizas E, Eden S, Yu Z, Sanchez-Garcia I, Gentles AJ, Roberts E, Bilbao-Cortes D, Vega F, Chapman J, Vertun R, Lossos I. LMO2 confers synthetic lethality to PARP inhibition in diffuse large B cell lymphoma. Cancer Cell 36(3):237-249, 2019. e-Pub 2019. PMID: 31447348.
105. Alvarez J, Algashaamy K, Tan Y, Mackrides N, Peng JH, Alderuccio JP, Alencar A, Vega F, Chapman J. Richter-like Pleomorphic Mantle Cell Lymphoma Composed of EBV-Positive Hodgkin-like Cells, a Diagnostic Challenge 24(5):235-239, 2019. e-Pub 2019.
106. Lossos C, Liu Y, Kolb KE, Christie AL, Van Scoyk A, Prakadan SM, Shigemori K, Stevenson KE, Morrow S, Plana OD, Fraser C, Jones KL, Liu H, Pallasch CP, Modiste R, Nguyen QD, Craig JW, Morgan EA, Vega F, Aster JC, Sarosiek KA, Shalek AK, Hemann MT, Weinstock DM. Mechanisms of Lymphoma Clearance Induced by High-Dose Alkylating Agents. Cancer Discov 9(7):944-961, 2019. e-Pub 2019. PMID: 31040105.
107. Rajan SS, Li L, Kweh MF, Kunkalla K, Amin A, Agarwal N, Vega F, Schatz JH. CRISPR genome editing of murine hematopoietic stem cells to create NPM1-ALK causes ALK positive lymphoma after transplantation Blood advances. Blood Advances 3(12):1788-1794, 2019. e-Pub 2019. PMID: 31189527.
108. Husnain M, Mackrides N, Vega F, Paez-Escamilla M, Markoe AM, Harbour JW, Lossos IS. CD4+/CD8+ immunophenotype switching as a marker for intraocular and CNS involvement in mycosis fungoides. Leuk Lymphoma 60(5):1308-1311, 2019. e-Pub 2019. PMID: 30424702.
109. Alderuccio JP, Zhao W, Desai A, Ramdial J, Gallastegui N, Kimble E, de la Fuente MI, Husnain M, Rosenblatt JD, Alencar AJ, Schatz JH, Moskowitz CH, Chapman JR, Vega F, Reis IM, Lossos IS. Short survival and frequent transformation in extranodal marginal zone lymphoma with multiple mucosal sites presentation. Am J Hematol 94(5):585-596, 2019. e-Pub 2019. PMID: 30784098.
110. Khashab T, Hagemeister F, Romaguera JE, Fanale MA, Pro B, McLaughlin P, Rodriguez MA, Neelapu SS, Fayad L, Younes A, Feng L, Vega F, Kwak LW, Samaniego F. Long-term overall- and progression-free survival after pentostatin, cyclophosphamide and rituximab therapy for indolent non-Hodgkin lymphoma. Br J Haematol 185(4):670-678, 2019. e-Pub 2019. PMID: 30820940.
111. Kim CH, Chapman JR, Vega F. A case of EBV-associated blastic lymphoplasmacytic proliferation in an oesophageal ulcer with a self-limiting course: overlapping lesion between EBV mucocutaneous ulcer and polymorphic lymphoplasmacytic disorder. Histopathology 74(6):964-966, 2019. e-Pub 2019. PMID: 30725484.
112. Mackrides M, Chapman J, Larson MC, Ramos JC, Toomey N, Lin P, Maurer MJ, Rafaelle M, Tan Y, Ikpatt F, Syrbu S, Ansell S, Habermann TM, Link BK, Feldman A, Lossos IS, Cerhan J, Vega F. Prevalence, clinical characteristics and prognosis of EBV-positive follicular lymphoma. Am J Hematol 94(2):E62-E64, 2019. e-Pub 2019. PMID: 30474261.
113. Alderuccio JP, Mackrides N, Chapman JR, Vega F, Lossos IS. Rapid complete response to blinatumomab as a successful bridge to allogeneic stem cell transplantation in a case of refractory Richter syndrome. Leuk Lymphoma 60(1):230-233, 2019. e-Pub 2019. PMID: 29745744.
114. Mackrides N, Lossos IS, Vega F. Intracytoplasmic azurophilic inclusions in prolymphocytes. International journal of hematology 108(6):565, 2018. e-Pub 2018. PMID: 30302738.
115. Lu X, Fernando TM, Lossos C, Yusufova N, Liu F, Fontán L, Durant M, Geng H, Melnick J, Luo Y, Vega F, Moy V, Inghirami G, Nimer S, Melnick AM, Lossos IS. PRMT5 interacts with the BCL6 oncoprotein and is required for germinal center formation and lymphoma cell survival. Blood 132(19):2026-2039, 2018. e-Pub 2018. PMID: 30082494.
116. Qu C, Kunkalla K, Vaghefi A, Frederiksen JK, Liu Y, Chapman JR, Blonska M, Bernal-Mizrachi L, Alderuccio JP, Lossos IS, Landgraf R, Vega F. Smoothened stabilizes and protects TRAF6 from degradation: A novel non-canonical role of smoothened with implications in lymphoma biology. Cancer Lett 436:149-158, 2018. e-Pub 2018. PMID: 30165192.
117. Alderuccio JP, Zhao W, Desai A, Gallastegui N, Ramdial J, Kimble E, de la Fuente MI, Rosenblatt JD, Chapman JR, Vega F, Reis IM, Lossos IS. Risk Factors for Transformation to Higher-Grade Lymphoma and Its Impact on Survival in a Large Cohort of Patients With Marginal Zone Lymphoma From a Single Institution. J Clin Oncol 36(34):JCO1800138, 2018. e-Pub 2018. PMID: 30312133.
118. Chapman J, Vega F. Monotypic and IgH-rearranged lymphoplasmacytic cells restricted to the light zone of germinal centers: an early (in situ?) marginal zone lymphoma?. Ann Hematol 97(10):1999-2000, 2018. e-Pub 2018. PMID: 29725761.
119. Peters TL, Tillotson J, Yeomans AM, Wilmore S, Lemm E, Jiménez-Romero C, Amador LA, Li L, Amin AD, Pongtornpipat P, Zerio CJ, Ambrose AJ, Paine-Murrieta G, Greninger P, Vega F, Benes CH, Packham G, Rodríguez AD, Chapman E, Schatz JH. Target-Based Screening against eIF4A1 Reveals the Marine Natural Product Elatol as a Novel Inhibitor of Translation Initiation with In Vivo Antitumor Activity. Clin Cancer Res 24(17):4256-4270, 2018. e-Pub 2018. PMID: 29844128.
120. Alderuccio JP, Stefanovic A, Dammrich D, Chapman JR, Vega F, Selvaggi G, Tzakis A, Lossos IS. Decreased survival in hepatitis C patients with monomorphic post-transplant lymphoproliferative disorder after liver transplantation treated with frontline immunochemotherapy. Leuk Lymphoma 59(9):2096-2104, 2018. e-Pub 2018. PMID: 29252057.
121. Khanlari M, Ramos JC, Sanchez SP, Cho-Vega JH, Amador A, Campuzano-Zuluaga G, Vega F, Chapman JR. Adult T-cell leukemia/lymphoma can be indistinguishable from other more common T-cell lymphomas. The University of Miami experience with a large cohort of cases. Mod Pathol 31(7):1046-1063, 2018. e-Pub 2018. PMID: 29449683.
122. Greenblatt SM, Man N, Hamard PJ, Asai T, Karl D, Martinez C, Bilbao D, Stathias V, Jermakowicz AM, Duffort S, Tadi M, Blumenthal E, Newman S, Vu L, Xu Y, Liu F, Schurer SC, McCabe MT, Kruger RG, Xu M, Yang FC, Tenen DG, Watts J, Vega F, Nimer SD. CARM1 Is Essential for Myeloid Leukemogenesis but Dispensable for Normal Hematopoiesis. Cancer Cell 33(6):1111-1127.e5, 2018. e-Pub 2018. PMID: 29894694.
123. Bini Viotti J, Doblecki S, Luca CC, Mackrides N, Vega F, Alcaide ML. Primary Intramedullary Spinal Cord Lymphoma Presenting as a Cervical Ring-Enhancing Lesion in an AIDS Patient. Open Forum Infect Dis 5(6):ofy128, 2018. e-Pub 2018. PMID: 29951566.
124. Alderuccio JP, Desai A, Yepes MM, Chapman JR, Vega F, Lossos IS. Frontline brentuximab vedotin in breast implant-associated anaplastic large-cell lymphoma. Clin Case Rep 6(4):634-637, 2018. e-Pub 2018. PMID: 29636930.
125. Chapman J, Geyer JT, Khanlari M, Moul A, Casas C, Connor ST, Fan YS, Watts JM, Swords RT, Vega F, Orazi A. Myeloid neoplasms with features intermediate between primary myelofibrosis and chronic myelomonocytic leukemia. Mod Pathol 31(3):429-441, 2018. e-Pub 2018. PMID: 29192651.
126. Algashaamy K, Tan Y, Mackrides N, Alencar A, Peng JH, Rosenblatt J, Alderuccio JP, Lossos IS, Vega F, Chapman J. Splenic B-Cell Lymphomas with Diffuse Cyclin D1 Protein Expression and Increased Prolymphocytic Cells: A Previously Unrecognized Diagnostic Pitfall. Case Rep Hematol 2018, 2018. e-Pub 2018. PMID: 30363761.
127. Swords RT, Azzam D, Al-Ali H, Lohse I, Volmar CH, Watts JM, Perez A, Rodriguez A, Vargas F, Elias R, Vega F, Zelent A, Brothers SP, Abbasi T, Trent J, Rangwala S, Deutsch Y, Conneally E, Drusbosky L, Cogle CR, Wahlestedt C. Ex-vivo sensitivity profiling to guide clinical decision making in acute myeloid leukemia: A pilot study. Leuk Res 64:34-41, 2018. e-Pub 2018. PMID: 29175379.
128. Viotti, JB, Doblecki-Lewis, S, Luca, CC, Mackrides, N, Vega, F, Alcaide, ML. Primary intramedullary spinal cord lymphoma presenting as a cervical ring-enhancing lesion in an AIDS patient. Open Forum Infectious Diseases 5(6), 2018. e-Pub 2018.
129. Cassidy DP, Vega F, Chapman JR. Epstein-Barr Virus-Positive Extranodal Marginal Zone Lymphoma of Bronchial-Associated Lymphoid Tissue in the Posttransplant Setting: An Immunodeficiency-Related (Posttransplant) Lymphoproliferative Disorder?. Am J Clin Pathol 149(1):42-49, 2017. e-Pub 2017. PMID: 29228090.
130. Wu SC, Chapman JR, Vega F, Abrahams N, Lossos IS, Alderuccio JP. Hepatosplenic T-cell lymphoma associated with membranoproliferative glomerulonephritis. Leuk Lymphoma 58(11):2734-2737, 2017. e-Pub 2017. PMID: 28351190.
131. Chapman J, Vega F. Incidental brown adipose tissue in bone marrow biopsy. Blood 130(7):952, 2017. e-Pub 2017. PMID: 28818979.
132. Watts JM, Perez A, Pereira L, Fan YS, Brown G, Vega F, Petrie K, Swords RT, Zelent A. A Case of AML Characterized by a Novel t(4;15)(q31;q22) Translocation That Confers a Growth-Stimulatory Response to Retinoid-Based Therapy. Int J Mol Sci 18(7), 2017. e-Pub 2017. PMID: 28696354.
133. De la Fuente MI, Haggiagi A, Moul A, Young RJ, Sidani C, Markoe A, Vega F, DeAngelis LM, Lossos IS. Marginal zone dural lymphoma: the Memorial Sloan Kettering Cancer Center and University of Miami experiences. Leuk Lymphoma 58(4):882-888, 2017. e-Pub 2017. PMID: 27649904.
134. Mackrides N, Campuzano-Zuluaga G, Maque-Acosta Y, Moul A, Hijazi N, Ikpatt FO, Levy R, Verdun RE, Kunkalla K, Natkunam Y, Lossos IS, Vega F, Chapman J. Epstein-Barr virus-positive follicular lymphoma. Mod Pathol 30(4):519-529, 2017. e-Pub 2017. PMID: 27982024.
135. Bhatt S, Parvin S, Zhang Y, Cho HM, Kunkalla K, Vega F, Timmerman JM, Shin SU, Rosenblatt JD, Lossos IS. Anti-CD20-interleukin-21 fusokine targets malignant B cells via direct apoptosis and NK-cell-dependent cytotoxicity. Blood 129(16):2246-2256, 2017. e-Pub 2017. PMID: 28137826.
136. Villada G, Vega F. Clusters of paracortical plasmacytoid dendritic cells in lupus lymphadenitis. Blood 129(13):1884, 2017. e-Pub 2017. PMID: 28360360.
137. Alderuccio JP, Amarapurkar P, Chapman JR, Vega F, Lossos IS. Characteristics and outcomes of lymphoblastic lymphoma - the University of Miami experience. Leuk Lymphoma 58(1):195-198, 2017. e-Pub 2017. PMID: 27252116.
138. Desai A, Joag MG, Lekakis L, Chapman JR, Vega F, Tibshirani R, Tse D, Markoe A, Lossos IS. Long-term course of patients with primary ocular adnexal MALT lymphoma: a large single-institution cohort study. Blood 129(3):324-332, 2017. e-Pub 2017. PMID: 27789481.
139. Lyapichev KA, Chapman JR, Iakymenko O, Ikpatt OF, Teomete U, Sanchez SP, Vega F. Bone Marrow-Liver-Spleen Type of Large B-Cell Lymphoma Associated with Hemophagocytic Syndrome: A Rare Aggressive Extranodal Lymphoma. Case Rep Hematol 2017:8496978, 2017. e-Pub 2017. PMID: 28835859.
140. Gil VS, Bhagat G, Howell L, Zhang J, Kim CH, Stengel S, Vega F, Zelent A, Petrie K. Deregulated expression of HDAC9 in B cells promotes development of lymphoproliferative disease and lymphoma in mice. Dis Model Mech 9(12):1483-1495, 2016. e-Pub 2016. PMID: 27799148.
141. Cortizas EM, Zahn A, Safavi S, Reed JA, Vega F, Di Noia JM, Verdun RE. UNG protects B cells from AID-induced telomere loss. J Exp Med 213(11):2459-2472, 2016. e-Pub 2016. PMID: 27697833.
142. Kozloski GA, Jiang X, Bhatt S, Ruiz J, Vega F, Shaknovich R, Melnick A, Lossos IS. miR-181a negatively regulates NF-κB signaling and affects activated B-cell-like diffuse large B-cell lymphoma pathogenesis. Blood 127(23):2856-66, 2016. e-Pub 2016. PMID: 26941399.
143. Campuzano-Zuluaga G, Ortiz D, Peng JH, Francis Ikpatt O, Fan YS, Barredo JC, Vega F, Chapman JR. Primary Mediastinal Large B-Cell Lymphoma With Translocations Involving BCL6 and MYC (Double-Hit Lymphoma). Am J Clin Pathol 145(5):710-6, 2016. e-Pub 2016. PMID: 27124935.
144. Yabe M, Medeiros LJ, Tang G, Wang SA, Ahmed S, Nieto Y, Hu S, Bhagat G, Oki Y, Patel KP, Routbort M, Luthra R, Fanale MA, Bueso-Ramos CE, Jorgensen JL, Vega F, Chen W, Hoehn D, Konoplev S, Milton DR, Wistuba I, Li S, You MJ, Young KH, Miranda RN. Prognostic Factors of Hepatosplenic T-cell Lymphoma: Clinicopathologic Study of 28 Cases. Am J Surg Pathol 40(5):676-88, 2016. e-Pub 2016. PMID: 26872013.
145. Campuzano-Zuluaga G, Deutsch Y, Salzberg M, Gomez A, Vargas F, Elias R, Kwon D, Goodman M, Ikpatt OF, Chapman JR, Watts J, Vega F, Swords R. Routine interim disease assessment in patients undergoing induction chemotherapy for acute myeloid leukemia: Can we do better?. Am J Hematol 91(3):277-82, 2016. e-Pub 2016. PMID: 26663264.
146. Agarwal NK, Kim CH, Kunkalla K, Konno H, Tjendra Y, Kwon D, Blonska M, Kozloski GA, Moy VT, Verdun RE, Barber GN, Lossos IS, Vega F. Active IKKβ promotes the stability of GLI1 oncogene in diffuse large B-cell lymphoma. Blood 127(5):605-15, 2016. e-Pub 2016. PMID: 26603838.
147. Chapman J, Gentles AJ, Sujoy V, Vega F, Dumur CI, Blevins TL, Bernal-Mizrachi L, Mosunjac M, Pimentel A, Zhu D, Lossos IS. Gene expression analysis of plasmablastic lymphoma identifies downregulation of B-cell receptor signaling and additional unique transcriptional programs. Leukemia 29(11):2270-3, 2015. e-Pub 2015. PMID: 25921246.
148. Blonska M, Agarwal NK, Vega F. Shaping of the tumor microenvironment: Stromal cells and vessels. Semin Cancer Biol 34:3-13, 2015. e-Pub 2015. PMID: 25794825.
149. Vega F, Medeiros LJ, Bueso-Ramos CE, Arboleda P, Miranda RN. Hematolymphoid neoplasms associated with rearrangements of PDGFRA, PDGFRB, and FGFR1. Am J Clin Pathol 144(3):377-92, 2015. e-Pub 2015. PMID: 26276769.
150. Zhu D, Bhatt S, Lu X, Guo F, Veelken H, Hsu DK, Liu FT, Alvarez Cubela S, Kunkalla K, Vega F, Chapman-Fredricks JR, Lossos IS. Chlamydophila psittaci-negative ocular adnexal marginal zone lymphomas express self polyreactive B-cell receptors. Leukemia 29(7):1587-99, 2015. e-Pub 2015. PMID: 25676418.
151. Ruiz-Cordero, R, Lewis, J, Blieden, C, Campuzano-Zuluaga, G, Hernandez, J, Lossos, IS, Ikpatt, O, Chapman, J, Vega, F. Unusual immunophenotypic variant of large B-cell lymphoma associated with HHV-8 and EBV in an HIV positive patient. Human Pathology: Case Reports 2(2):49-54, 2015. e-Pub 2015.
152. Samaniego F, Hagemeister F, Romaguera JE, Fanale MA, Pro B, McLaughlin P, Rodriguez MA, Neelapu SS, Fayad L, Younes A, Feng L, Berkova Z, Khashab T, Sehgal L, Vega, Kwak LW. Pentostatin, cyclophosphamide and rituximab for previously untreated advanced stage, low-grade B-cell lymphomas. Br J Haematol 169(6):814-23, 2015. e-Pub 2015. PMID: 25828695.
153. Blonska M, Zhu Y, Chuang HH, You MJ, Kunkalla K, Vega F, Lin X. Jun-regulated genes promote interaction of diffuse large B-cell lymphoma with the microenvironment. Blood 125(6):981-91, 2015. e-Pub 2015. PMID: 25533033.
154. Ruiz-Cordero R, Chapman J, Vega F. Synaptophysin is frequently expressed in megakaryocytes: a novel immunohistochemical finding of unknown significance(62):76-80, 2015. e-Pub 2015.
155. Ruiz-Cordero, R, Lewis J, Blieden C, Campuzano-Zuluaga G, Hernandez J, Lossos IS, Ikpatt F, Chapman JR, Vega F. Unusual immunophenotypic variant of large B-cell lymphoma associated with HHV-8 and EBV in an HIV positive patient 2:49-54, 2015. e-Pub 2015.
156. Blieden C, Fan YS, Chapman JR, Vega F. De novo acute myeloid leukemia with monocytoid blasts and erythrophagocytosis. Clin Case Rep. Clinical Case Reports 2(6):333-5, 2014. e-Pub 2014. PMID: 25548641.
157. Blieden C, Medeiros LJ, Vega F. Acquired B-cell immunophenotype of follicular dendritic cells in a B-cell depleted lymph node after treatment with rituximab Ann Hematol. Annals of Hematology 93(11):1947-8, 2014. e-Pub 2014. PMID: 24752418.
158. Blieden C, Campuzano-Zuluaga G, Moul A, Chapman JR, Cioffi-Lavina, Ikpatt OF Byrne GE, Vega F. Anaphylactic Reaction to Platelet Transfusion as the Initial Symptom of an Undiagnosed Systemic Mastocytosis: A Case Report and Review of the Literature. Journal of Medical Case Reports 26(1):26-8,389, 2014. e-Pub 2014. PMID: 25424186.
159. Chapman-Fredricks J, Sandoval-Sus J, Vega F, Lossos IS. Progressive Leukemic Non-nodal Mantle Cell Lymphoma Associated with Deletions of TP53, ATM, and / or 13q14. Annals of Diagnostic Pathology 18(4):214-9, 2014. e-Pub 2014. PMID: 24852242.
160. Gera S, Dekmezian MS, Duvic M, Tschen J, Vega F, Cho-Vega JH. Blastic plasmacytoid dendritic cell neoplasm;evolving insights in an aggressive hematopoatic malignancy with a prediction of skin involvement. Am J Dermatopathol 36(3):244-51, 2014. e-Pub 2014. PMID: 24247574.
161. Cho-Vega JH, Vega F. CD30-negative lymphomatoid papulosis type D in an elderly man. American Journal of Dermatopathology 36(2):190-2, 2014. e-Pub 2014. PMID: 24394303.
162. Leventaki V, Oki Y, Romaguera J, Vega F. Indolent Peripheral T-Cell Lymphoma Involving the Gastrointestinal Tract. Human Pathology 45(2):421-6, 2014. e-Pub 2014. PMID: 24439229.
163. Oki Y, Westin JR, Vega F, Chuang H, Fowler N, Neelapu S, Hagemeister FB, McLaughlin P, Kwak LW, Romaguera JE, Fanale M, Younes A, Rodriguez MA, Orlowski RZ, Wang M, Ouzounian ST, Samaniego F, Fayad L. Prospective phase II study of rituximab with alternating cycles of hyper-CVAD and high-dose methotrexate with cytarabine for young patients with high-risk diffuse large B-cell lymphoma. Br J Haematol 163(5):611-20, 2013. e-Pub 2013. PMID: 24117234.
164. Vega F. Time to look for CD30 expression in diffuse large B cell lymphomas, along the way to immunotherapy. Leuk Lymphoma 54(11):2341-2, 2013. e-Pub 2013. PMID: 23472971.
165. Sánchez-Espiridión B, Martín-Moreno AM, Montalbán C, Figueroa V, Vega F, Younes A, Medeiros LJ, Alvés FJ, Canales M, Estévez M, Menarguez J, Sabín P, Ruiz-Marcellán MC, Lopez A, Sánchez-Godoy P, Burgos F, Santonja C, López JL, Piris MA, Garcia JF. MicroRNA signatures and treatment response in patients with advanced classical Hodgkin lymphoma. Br J Haematol 162(3):336-47, 2013. e-Pub 2013. PMID: 23725219.
166. Kunkalla L, Liu Y, Changju Q, Leventaki V, Agarwal NK, Singh R, Vega F. Functional inhibition of BCL2 is needed to increase the susceptibility to apoptosis to SMO Inhibitors in diffuse large B-cell Lymphoma of germinal center subtype. Annals Hematol 92(6):777-87, 2013. e-Pub 2013. PMID: 23370596.
167. Rawal S, Chu F, Zhang M, Park HJ, Nattamai D, Kannan S, Sharma R, Delgado D, Chou T, Lin HY, Baladandayuthapani V, Luong A, Vega F, Fowler N, Dong C, Davis RE, Neelapu SS. Cross Talk between Follicular Th Cells and Tumor Cells in Human Follicular Lymphoma Promotes Immune Evasion in the Tumor Microenvironment. J Immunol 190(12):6681-6693, 2013. e-Pub 2013. PMID: 23686488.
168. Qu C, Liu Y, Kunkalla K, Singh RR, Blonska M, Lin X, Agarwal NK, Vega F. Trimeric G protein-CARMA1 axis links smoothened, the hedgehog receptor transducer, to NF-KB activation in diffuse large B-cell lymphoma. Blood 121(23):4718-28, 2013. e-Pub 2013. PMID: 23632891.
169. Jain P, Vega, Faderl S. "Cup-like" blasts and NPM1 and FLT3 (ITD) mutations in acute myeloid leukemia (AML). Int J Hematol 98(1):3, 2013. e-Pub 2013. PMID: 23690292.
170. Agarwal NK, Qu C, Kunkalla K, Liy Y, Vega F. Transcriptional Regulation of Serine/Threonine Protein Kinase (AKT) Genes by Glioma-Associated Oncogene Homolog 1. J Biol Chem 288(21):15390-401, 2013. e-Pub 2013. PMID: 23580656.
171. Li S, Feng X, Li T, Zhang S, Zuo Z, Lin P, Konoplev S, Bueso-Ramos CE, Vega F, Medeiros LJ, Yin CC. Extranodal NK/T-cell Lymphoma, Nasal Type: A Report of 73 Cases at MD Anderson Cancer Center. Am J Surg Pathol 37(1):14-23, 2013. e-Pub 2013. PMID: 23232851.
172. Merrit BY, Curry JL, Duvic M, Vega F, Sheehan AM, Curry CV. Pediatric subcutaneous panniculitis-like T-cell lymphoma with features of hemophagocytic syndrome. Pediatric Blood Cancer 60(11):1916-7, 2013. e-Pub 2013. PMID: 23868752.
173. Handal B, Entow R, Lara D, Bailey M, Vega F, Hu P, Lennon A. Investigating the expression of oncogenic and tumor suppressive microRNA in DLBCL 39(1):14-20, 2013. e-Pub 2013. PMID: 26030163.
174. Kanagal-Shamanna R, Medeiros LJ, Lu G, Wang SA, Manning JT, Lin P, Penn GM, Young KH, You MJ, Vega F, Bassett R, Miranda RN. High-grade B cell lymphoma, unclassifiable, with blastoid features: an unusual morphological subgroup associated frequently with BCL2 and/or MYC gene rearrangements and a poor prognosis. Histopathology 61(5):945-54, 2012. e-Pub 2012. PMID: 22804688.
175. Ramirez E, Singh RR, Kunkalla K, Liu Y, Qu C, Cain C, Multani AS, Lennon PA, Jackacky J, Ho M, Dawud S, Gu J, Yang S, Hu PC, Vega F. Defining causative factors contributing in the activation of hedgehog signaling in diffuse large B-cell lymphoma. Leuk Res 36(10):1267-73, 2012. e-Pub 2012. PMID: 22809693.
176. Greaves WO, Xiao L, Sanchez-Espiridion B, Kunkalla K, Dave KS, Liang CS, Singh RR, Younes A, Medeiros LJ, Vega F. Detection of ABCC1 expression i classical Hodgkin Lymphoma is associated with increased risk of treatment failure using standard chemotherapy protocols. J Hematol Oncol 5:47, 2012. e-Pub 2012. PMID: 22871336.
177. Buglio D, Palakurthi S, Byth K, Vega F, Toader D, Saeh J, Neelapu SS, Younes A. Essential role of TAK1 in regulating mantle cell lymphoma survival. Blood 120(2):347-55, 2012. e-Pub 2012. PMID: 22649101.
178. Sánchez-Espiridión B, Martin-Moreno AM, Montalbán C, Medeiros LJ, Vega F, Younes A, Piris MA, Garcia JF. Immunohistochemical markers for tumor associated macrophages and survival in advanced classical Hodgkin's lymphoma. Haematologica 97(7):1080-4, 2012. e-Pub 2012. PMID: 22315492.
179. Kim Y, Leventaki V, Bhaijee F, Jackson CC, Medeiros LJ, Vega F. Extracavitary/Solid Variant of Primary Effusion Lymphoma. Ann Diagn Pathol 16(6):441-6, 2012. e-Pub 2012. PMID: 22497739.
180. Li C, Thompson MA, Tamaya AT, Zuo Z, Lee J, Vega F, Ford RJ, Pham LV. Over-expression of thioredoxin-1 mediates growth, survival, and chermoresistance aand is a drugable target in diffuse large B-cell lymphoma. Oncotarget 3(3):314-326, 2012. e-Pub 2012. PMID: 22447839.
181. Moretti L, Medeiros LJ, Kunkalla K, Williams MD, Singh RR, Vega F. N-terminal PAX8 polyclonal antibody shows cross-reactivity with N-terminal region of PAX5 and is responsible for reports of PAX8 positivity in malignant lymphomas. Mod Path 25(2):231-6, 2012. e-Pub 2012. PMID: 22037256.
182. Meadows SA, Vega F, Kashishian A, Johnson D, Diehl V, Miller LL, Younes A, Lannutti BJ. PI3Kδ inhibitor, GS-1101 (CAL-101), attentuates pathway signaling, induces apoptosis, and overcomes signals from the microenvironment in cellular models of Hodgkin lymphoma. Blood 119(8):1897-900, 2012. e-Pub 2012. PMID: 22210877.
183. Ok CH, Singh RR, Vega F. Aberrant activation of the hedgehog signaling pathway in malignant hematological neoplasms. Am J Pathol 180(1):2-11, 2012. e-Pub 2012. PMID: 22056910.
184. Cho-Vega JH, Tschen JA, Vega F. CD4 CD8 Double-Negative Early Stage Mycosis Fungoides Associated with Primary Cutaneous Follicular Center Lymphoma. J Am Acad Dermatol 65(4):884-6, 2011. e-Pub 2011. PMID: 21920253.
185. Greaves WO, Kim JE, Singh RR, Drakos E, Kunkalla K, Sánchez-Espiridión B, Garcia JF, Medeiros LJ, Vega F. Glioma associated oncogene homologue 3 (GLI3), a Hedgehog transcription factor, is highly expressed in hodgkin and Reed-Sternberg cells of Classical Hodgkin lymphoma. Hum Pathol 42(11):1643-52, 2011. e-Pub 2011. PMID: 21531006.
186. Drakos E, Leventaki V, Atsaves V, Schlette EJ, Lin P, Vega F, Miranda RN, Claret FX, Medeiros LJ, Rassidakis GZ. Expression of serine 194-phosphorylated Fas-associated death domain protein correlates with proliferation in B-cell non-Hodgkin-type lymphomas. Hum Pathol 42(8):1117-24, 2011. e-Pub 2011. PMID: 21315423.
187. Vishwamitra D, Shi P, Wilson D, Manshouri R, Vega F, Schlette EJ, Amin HM. Expression and effects of inhibition of IGF-IR tyrosine kinase in mantle cell lymphoma. Haematologica 96(6):871-90, 2011. e-Pub 2011. PMID: 21330319.
188. Huh YO, Schweighofer CD, Ketterling RP, Knudson RA, Vega F, Kim JE, Luthra R, Keating MJ, Medeiros LJ, Abruzzo LV. Chronic Lymphocytic Leukemia With t(14;19)(q32;q13) Is Characterized by Atypical Morphologic and Immunophenotypic Features and Distinctive Genetic Features. Am J Clin Pathol 135(5):686-96, 2011. e-Pub 2011. PMID: 21502423.
189. Drakos E, Singh RR, Rassidakis GZ, Schlette EJ, Li J, Claret FX, Ford RJ, Vega F, Medeiros LJ. Activation of p53 pathway by MDM2 inhibitor nutlin-3a overcomes BCL2 overexpression in a preclinical model of diffuse large B-cell lymphoma. Leukemia 25(5):856-67, 2011. e-Pub 2011. PMID: 21394100.
190. Hsu C, Vega F, Grimes LM, Hunt KK. Follicular dendritic cell sarcoma and associated myasthenia gravis: true, true, related?. J Clin Oncol 29(13):e369-71, 2011. e-Pub 2011. PMID: 21321294.
191. Curry LJ, Prieto VG, Jones DM, Vega F, Duvic M, Diwan AH. Transient iatrogenic immunodeficiency-related B-cell lymphoproliferative disorder of the skin in a patient with mycosis fungoides/Sezary syndrome. J Cutan Pathol 38(3):295-7, 2011. e-Pub 2011. PMID: 19889052.
192. Pham LV, Fu L, Tamayo AT, Bueso-Ramos C, Drakos E, Vega F, Medeiros LJ, Ford RJ. Constitutive BR3 receptor signaling in diffuse large B-cell lymphomas stabilizes NK-{kappa}B-inducing kinase, while activating both canonical and alternative NF-{kappa}B pathways. Blood 117(1):200-10, 2011. e-Pub 2011. PMID: 20889926.
193. Singh R, Kunkalla K, Qu C, Schlette E, Neelapu S, Samaniego F, Vega F. ABCG2 is a Direct Transcriptional Target of Hedgehog Signaling and Involved in Stroma-Induced Drug Tolerance in Diffuse Large B-Cell Lymphoma. Oncogene 30(49):4874-66, 2011. e-Pub 2011. PMID: 21625222.
194. Cho-Vega JH, Tschen J, Duvic M, Vega F. Early stage mycosis fungoides variants: Case based review. Ann Diagn Pathol 14(5):369-85, 2010. e-Pub 2010. PMID: 20850703.
195. Vega F, Davuluri Y, Cho-Vega JH, Ma S, Wang RU, Multani AS, Drakos I, Pham L, Shen L, Ambrus J, Medeiros LJ, Ford R. Side population contains cells with "tumor-initiating cell" features responsible for lymphoma maintenance and systemic dissemination. J Cell Mol Med 14(6B):1532-45, 2010. e-Pub 2010. PMID: 19656242.
196. Singh RR, Kim JE, Davuluri Y, Drakos-E, Cho-Vega JH, Amin H, Vega F. Hedgehog-signaling pathway contributes to tumor cell survival and proliferation in diffuse large B-cell lymphoma. Leukemia 24(5):1025-36, 2010. e-Pub 2010. PMID: 20200556.
197. Wang SA, Jabbark, Lu G, Chen SS, Galili N, Vega F, Jones D, Raza A, Kantarjian H, Garcia-Manero G, McDonnell TJ, Medeiros LJ. Trisomy 11 in myelodysplastic syndromes defines a unique group of disease with aggressive clinicopathologic features. Leukemia 24(4):740-7, 2010. e-Pub 2010. PMID: 20072149.
198. Vega F, Medeiros LJ. V(D)J recombination and staggered DNA breaks: guilty again. Blood 115(11):2121-2, 2010. e-Pub 2010. PMID: 20299518.
199. Khokhar FA, Payne WD, Talwalkar SS, Jorgensen J, Bueso-Ramos C, Medeiros LJ, Vega F. Angioimmunoblastic T-Cell Lymphoma in Bone Marrow: A Morphologic and Immunophenotypic Study. Hum Pathol 41(1):79-87, 2010. e-Pub 2010. PMID: 19740519.
200. Drakos E, Rassidakis RZ, Leventaki V, Cotta C, Vega F, Medeiros LJ. Nodular Lymphocyte predominant Hodgkin lymphoma with clusters of L&H-like cells, acute inflammation, and fibrosis: a syncitial variant. Am J Surg Pathol 33(11):1725-31, 2009. e-Pub 2009. PMID: 19730363.
201. Kim JE, Singh RR, Cho-Vega JH, Drakos E, Davuluri Y, Khokhar FA, Fayad L, Medeiros LJ, Vega F. Sonic hedgehog signaling proteins and ATP-binding cassette G2 are aberrantly expressed in diffuse large B-cell lymphoma. Mod Pathol 22(10):1312-20, 2009. e-Pub 2009. PMID: 19593328.
202. Falchook G, Vega F, Dang N, Samaniego F, Rofriguez M, Champlin R, Hosing C, Verstovsek S, Pro B. Hepatosplenic gamma-delta T-cell lymphoma: clinicopathological features and treatment. Ann Oncol 20(6):1080-1085, 2009. e-Pub 2009. PMID: 19237479.
203. Singh RR, Cho-Vega JH, Davuluri Y, Ma S, Kasbidi F, Milito C, Lennon PA, Drakos E, Medeiros LJ, Luthra R, Vega F. Sonic Hedgehog signaling pathway is activated in ALK-positive anaplastic large cell lymphoma. Cancer Res 69(6):2550-8, 2009. e-Pub 2009. PMID: 19244133.
204. Yang H, I-Chun Lin K, Vega F, Schlette E, Yin C, Keating M, Luthra R Medeiros LJ and Abruzzo L. MYC translocation in chronic lymphocytic leukemia is associated with increased prolymphocytes and a poor prognosis. Br J Haematol 142(1):36-44, 2008. e-Pub 2008. PMID: 18477041.
205. Quintas-Cardama A, Tong W, Manshouri T, Vega F, Lennon PA, Cools J, Gilliland DG, Lee F, Cortes J, Kantarjian H, Garcia-Manero G. Activity of tyrosine kinase inhibitors against human nup214-abl-positive T-cell malignancies. Leukemia 22(6):1117-1124, 2008. e-Pub 2008. PMID: 18401417.
206. Vega F, Cho-Vega JH, Lennon PA, Luthra MG, Bailey J, Breeden M, Jones D, Medeiros LJ, Luthra R. Splenic Marginal Zone Lymphomas are characterized by loss of Interstitial Regions of Chromosome 7q,7q31.32 and 7q36.2, that include protection of Telomere 1 (POT1) and Sonic Hedgehog (SHH) Genes. Br J Haematol 142(2):216-226, 2008. e-Pub 2008. PMID: 18492102.
207. Cho-Vega JH, Vega F, Medeiros LJ. An Attractive Therapeutic Target, mTOR Pathway, for an Effective Combinatorial Cancer Therapy in Anaplastic Lymphoma Kinase-Positive Anaplastic Large Cell Lymphoma. Adv Anat Pathol 15(2):105-12, 2008. e-Pub 2008. PMID: 18418091.
208. Cho-Vega JH, Medeiros LJ, Prieto VG, Vega F. Leukemia Cutis. Am J Clin Pathol 129(1):130-42, 2008. e-Pub 2008. PMID: 18089498.
209. Vega F, Medeiros LJ, Davuluri R, Cromwell CC, Alkan S, Abruzzo LV. t(8;13)-positive bilineal lymphomas:report of six cases. Am J Surg Pathol 32(1):14-20, 2008. e-Pub 2008. PMID: 18162765.
210. Jain N, Hubbard J, Vega F, Vidal G, Garcia-Manero G, Borthakur G. Spontaneous Remission of Acute Myeloid Leukemia:Report of Three Cases and Review of the Literature. Clin Leuk 2:64-67, 2008. e-Pub 2008.
211. Cho-Vega JH, Vega F, Schwartz MR, Prieto VG. Expression of dicarbonyl/L-xylulose reductase (DCXR) in human skin and melanocytic lesions:morphological studies supporting cell adhesion function of DCXR. J Cutan Pathol 34(7):535-542, 2007. e-Pub 2007. PMID: 17576332.
212. Vega F, Medeiros LJ, Gaulard P. Hepatosplenic and other gamma delta T-cell Lymphomas. Am J Clin Pathol 127(6):869-80, 2007. e-Pub 2007. PMID: 17509984.
213. Lin P, Jones D, Medeiros LJ, Chen W, Vega F, Luthra R. Activating FLT3 Mutations are detectable in Chronic and Blast Phase of Chronic Myeloproliferative Disorders other than Chronic Myeloid Leukemia. Am J Clin Pathol 126(4):530-3, 2006. e-Pub 2006. PMID: 16938665.
214. Vega F, Padula A, Valbuena JR, Stancu M, Jones D, Medeiros LJ. Systemic lymphomas involving the pleura. A Clinicopathologic study of 34 cases diagnosed by pleural biopsy. Arch Pathol Lab Med 130(10):1497-1502, 2006. e-Pub 2006. PMID: 17090191.
215. Vega F, Medeiros LJ, Leventaki V, Atwell C, Cho-Vega JH, Tian L, Claret FX, Rassidakis GZ. Activation of mTOR Signaling Pathway Contributes to Tumor Cell Survival in ALK-Positive Anaplastic Large Cell Lymphoma. Cancer Res 66(13):6589-97, 2006. e-Pub 2006. PMID: 16818631.
216. Cho-Vega JH, Vega F, Rassidakis G, Medeiros LJ. Primary Cutaneous Marginal Zone B-Cell Lymphoma. Am J Clin Pathol 125:S38-S49, 2006. e-Pub 2006. PMID: 16830956.
217. Vega F, Chang CC, Schwartz MR, Verm R, Preti HA, Etwon A, Younes M, Jaffe ES. Atypical NK-cell proliferation of the gastrointestinal tract in a patient with antigliadin antibodies but not celiac disease. Am J Surg Pathol 4(4):539-544, 2006. e-Pub 2006. PMID: 16625103.
218. Vega F, Coombes KR, Thomazy VA, Patel K, Lang W, Jones D. Tissue-Specific Function of Lymph Node Fibroblastic Reticulum Cells. Pathobiology 73(2):71-81, 2006. e-Pub 2006. PMID: 16943687.
219. Vega F, Lin P, Medeiros LJ. Extranodal lymphomas of the head and neck. Ann of Diagn Pathol 9(6):340-350, 2005. e-Pub 2005. PMID: 16308165.
220. Vega F, Chang CC, Medeiros LJ, Udden MM, Cho-Vega JH, Lau CC, Finch C, Vilchez RA, McGregor DK, Jorgensen JL. Plasmablastic lymphomas and plasmablastic plasma cells myelomas have nearly identical immunophenotypic profiles. Mod Pathol 18(6):806-815, 2005. e-Pub 2005. PMID: 15578069.
221. Cho-Vega JH, Rassidakis GZ, Amin HM, Tsioli P, Spurgers K, Remache YK, Vega F, Goy AH, Gilles F, Medeiros LJ. Suppressor of cytokine signaling 3 expression in anaplastic cell lymphoma. Leukemia 18(11):1872-1878, 2004. e-Pub 2004. PMID: 15385932.
222. Vega F, Medeiros LJ. Chromosomal translocations involved in non-Hodgkin lymphomas. Arch Pathol Lab Med 127(9):1148-1160, 2003. e-Pub 2003. PMID: 12946230.
223. Thomazy VA, Vega F, Medeiros LJ, Davis PJ, Jones D. Phenotypic modulation of the stromal reticular network in normal and neoplastic lymph nodes:transglutaminase reveals coordinate regulation. Am J Pathol 163(1):165-174, 2003. e-Pub 2003. PMID: 12819021.
224. Vega F, Luthra R, Medeiros LJ, Dunmire V, Lee SJ, Duvic M, Jones D. Clonal heterogeneity in mycosis fungoides and its relationship to clinical course. Blood 100(9):3369-3373, 2002. e-Pub 2002. PMID: 12384439.
225. Sanchez-Vega, B, Vega, F, Medeiros, LJ, Lee, MS, Luthra, R. Quantification of bcl-2/JH fusion sequences and a control gene by multiplex real-time PCR coupled with automated amplicon sizing by capillary electrophoresis. Journal of Molecular Diagnostics 4(4):223-229, 2002. e-Pub 2002. PMID: 12411590.
226. Stancu M, Jones D, Vega F, Medeiros LJ. Peripheral T-cell lymphoma arising in the liver. Am J Clin Pathol 118(4):574-581, 2002. e-Pub 2002. PMID: 12375645.
227. Vega F, Orduz R, Medeiros LJ. Chromosomal translocations and their role in the pathogenesis of non-Hodgkin's lymphomas. Pathology 34(5):397-409, 2002. e-Pub 2002. PMID: 12408337.
228. Vega F, Medeiros LJ, Lang WH, Mansoor A, Bueso-Ramos C, Jones D. The stromal composition of malignant lymphoid aggregates in bone marrow: variations in architecture and phenotype in different in different B-cell tumors. Br J Haematol 117(3):569-576, 2002. e-Pub 2002. PMID: 12028024.
229. Abruzzo LV, Rosales CM, Medeiros LJ, Vega F, Luthra R, Manning JT, Keating MJ, Jones D. Epstein-Barr virus positive B-cell lymphoproliferative disorders arising in immunodeficient patients previously treated with fludarabine for low-grade B-cell neoplasms. Am J Surg Pathol 26(5):630-636, 2002. e-Pub 2002. PMID: 11979093.
230. Sen F, Vega F, Medeiros LJ. Molecular genetic methods in the diagnosis of hematologic neoplasms. Semin Diagn Pathol 19(2):72-93, 2002. e-Pub 2002. PMID: 12036283.
231. Sanchez-Vega, B, Vega, F, Hai, S, Medeiros, LJ, Luthra, R. Real-time t(14;18)(q32;q21) PCR assay combined with high-resolution capillary electrophoresis. Modern Pathology 15(4):448-453, 2002. e-Pub 2002. PMID: 11950920.
232. Sanchez-Vega B, Vega F, Hai S, Medeiros LJ, Luthra R. Real-time t(14;18) PCR assay combined with high resolution PCR fragment analysis: A novel approach to monitor disease/tumor burden in follicular lymphoma patients. Mod Pathol 15:441-453, 2002. e-Pub 2002.
233. Vega F, Medeiros LJ, Luthra R. Taqman PCR in the detection and of chromosomal translocations in follicular lymphoma, mantle cell lymphoma and chronic myeloid leukemia. Internet J Pathol 2(1), 2002. e-Pub 2002.
234. Jones D, Vega F, Sarris AH, Medeiros LJ. A CD4 and CD8 "double-negative" immunophenotype in cutaneous T-cell lymphoma is predictive of an aggressive clinical course. Am J Surg Pathol 26:225-231, 2002. e-Pub 2002.
235. Onciu M, Lai R, Vega F, Bueso-Ramos C, Medeiros LJ. Precursor T-cell acute lymphoblastic leukemia in adults. Am J Clin Pathol 117(2):252-258, 2002. e-Pub 2002. PMID: 11863221.
236. Sanchez-Vega B, Vega F, Medeiros LJ, Lee MS, Luthra R. Quantification of BCL-2/JH fusion sequences and a control gene by multiplex real-time PCR coupled with automated amplicon sizing by capillary electrophoresis. J Mol Diagn 4:223-229, 2002. e-Pub 2002.
237. Jones, D, Vega, F, Sarris, AH, Medeiros, LJ. CD4- CD8- 'double-negative' cutaneous T-cell lymphomas share common histologic features and an aggressive clinical course. American Journal of Surgical Pathology 26(2):225-231, 2002. e-Pub 2002. PMID: 11812944.
238. Vega F, Medeiros LJ, Jones D, Abruzzo LV, Lai R, Manning J, Dunmire V, Luthra R. A novel 4-color PCR assay to assess T-cell receptor gamma gene rearrangements in lymphoproliferative lesions. Am J Clin Pathol 116(1):17-24, 2001. e-Pub 2001. PMID: 11447747.
239. Vega F, Medeiros LJ. Chromosomal translocations in Non-Hodgkins's lymphomas (Part II). Patologia 34:353-366, 2001. e-Pub 2001.
240. Vega F, Medeiros LJ. Marginal zone B-cell lymphoma of extranodal MALT-type. Molecular genetics provides new insides into pathogenesis. Adv Anat Pathol 8:313-326, 2001. e-Pub 2001.
241. Vega, F, Medeiros, LJ, Bueso-Ramos, CE, Jones, D, Lai, R, Luthra, R, Abruzzo, L. Hepatosplenic gamma/delta T-cell lymphoma in bone marrow. American journal of clinical pathology 116(3):410-419, 2001. e-Pub 2001. PMID: 11554170.
242. Calvo M, Firvida JL, Vega F, Salgado M, Garcia Mata J, Ruben M, Barreiro A. Wilms tumor in the adult. Arch Esp Urol 54:370-374, 2001. e-Pub 2001.
243. Vega, F, Medeiros, LJ, Abruzzo, L. Primary paratesticular lymphoma. Archives of Pathology and Laboratory Medicine 125(3):428-432, 2001. e-Pub 2001. PMID: 11231498.
244. Vega F, Medeiros LJ, Abruzzo LV. Primary paratesticular lymphoma:a report of two cases and literature review. Arch Patol Lab Med 125:428-432, 2001. e-Pub 2001.
245. Vega F, Medeiros LJ, Bueso-Ramos C, Jones D, Lai R, Luthra R, Abruzzo LV. Hepatosplenic T-cell lymphoma in bone marrow: An intra-sinusoidal neoplasm with blastic cytologic features. Am J Clin Pathol 116:410-419, 2001. e-Pub 2001.
246. Vega F, Medeiros LJ. Chromosomal translocations in Non-Hodgkin's lymphomas (Part I). Patologia 34:277-286, 2001. e-Pub 2001.
247. Panizo A, Sola I, Vega F, de Alava E, Lozano MD, Idoate MA, Pardo-Mindan FJ. Predicting metastatic risk of gastrointestinal stromal tumors:role of cell proliferation and cell cycle regulatory proteins. Int J Surg Pathol 8(2):133-144, 2000. e-Pub 2000. PMID: 11493978.
248. Olivieri, DN, Vega, F. Image prototype similarity matching for lymph node hemopathology. Proceedings - International Conference on Pattern Recognition 15(2):279-282, 2000. e-Pub 2000.
249. Olivieri DN, Vega F. Image prototype similarity matching for lymph node hematopathology. Proceedings - International Conference on Pattern Recognition 15(2):279-282, 2000. e-Pub 2000.
250. Rodriguez-Gomez M, Fernandez-Sueiro JL, Willisch A, Fernandez-Dominguez L, Lopez-Barros G, Vega F. Multifocal dactylitis as the sole clinical expression of sarcoidosis. J Rheumatol 27(1):245-247, 2000. e-Pub 2000. PMID: 10648047.
251. Vega F, Diaz MS. Extramedullary hematopoiesis in polyposis. Gastrointest Endosc 51(3):330-331, 2000. e-Pub 2000. PMID: 10699782.
252. Vega F, Panizo A, Diez, Pardo-Mindan FJ. Susceptibility to apoptosis of arterioles and capillaries in adult spontaneously hypertensive rats. Am J Hypertens 12(8):815-820, 1999. e-Pub 1999. PMID: 10480475.
253. Vega F, Lozano MD, Alcade J, Pardo-Mindan FJ. Role of the immunohistochemical and molecular biology in necrotic lymph node. Virchows Arch 434:245-248, 1999. e-Pub 1999.
254. Vega, F, Lozano, MD, Alcalde, J, Pardo-Mindan, FJ. Utility of immunophenotypic and immunogenotypic analysis in the study of necrotic lymph nodes. Virchows Archiv 434(3):245-248, 1999. e-Pub 1999. PMID: 10190305.
255. Pastrana J, Conchillo MA, Vega F, Beloqui O. Granulomatosis linfomatoide pulmonar asociada a SIDA. Descripcion de un caso y revision de la literatura. An Med Interna 15:487-489, 1998. e-Pub 1998.
256. Pastrana Delgado, J, Conchillo Armendáriz, MA, Vega, F, Beloqui Ruiz, O. Granulomatosis linfomatoide pulmonar asociada a SIDA. A propósito de un caso y revisión de la literatura. Anales de medicina interna (Madrid, Spain : 1984) 15(9):487-489, 1998. e-Pub 1998. PMID: 10079542.
257. Diez J, Panizo A, Hernandez M, Vega F Sola I, Fortuno MA, Pardo J. Cardiomyocyte apoptosis and cardiac angiotensin-converting enzyme in spontaneously hypertensive rats. Hypertension 30(5):1029-1034, 1997. e-Pub 1997. PMID: 9369251.
258. Vega F, Errasti F, Pardo-Mindan FJ. Renal Transplantation from a donor with a Nail-Patella Syndrome. Nephr Dyal Transp 12(8):1742-1744, 1997. e-Pub 1997. PMID: 9269666.
259. Roth MS, Martin AB, Katz JA. Nutritional implications of prolonged propofol use. Am J Health Syst Pharm 54(6):694-5, 1997. e-Pub 1997. PMID: 9075502.
260. Arriagada C, Leyes, M, Valenti JR, Vega F. Papel de la artroscopia en la condrocalcinosis. Cuadren Artroscopia 4:21-25, 1997. e-Pub 1997.
261. Idoate, MA, Vega, F. Diagnostico de las enfermedades neurometabolicas y neurodegenerativas mediante biopsia cutanea. Revista de Neurologia 25(SUPPL. 3):S269-S280, 1997. e-Pub 1997. PMID: 9273173.
262. Panizo A, Vega F. Revision de la tecnica del TUNEL. Patologia 30:243-245, 1997. e-Pub 1997.
263. Idoate MA, Vega F. Diagnostico de las enfermedades neurometabolicas y neurodegenerativas mediante biopsia cutanea. Rev Neurol 25:S269-S280, 1997. e-Pub 1997.
264. Panizo A, Vega F. Glosario de biologia molecular. Patologia 30:259-260, 1997. e-Pub 1997.
265. Perez-Requena J, Vega F, Guezmez Domingo A, Ruiz ML, Paloma Gonzalez MJ, l D. Gliomatosis peritoneal: presentacion de los casos asociados a gliomatosis ganglionar y ovarica y elevacion de las concentraciones de alfa-fetoproteina. Patologia 30:150-153, 1997. e-Pub 1997.
266. Vega F, Díaz L, Castro L, Panizo A, Sierrasesúmaga L, Pardo-Mindán J. [Lymphatic metastases of osteosarcomas]. Rev Med Univ Navarra 40(3):27-30, 1996. e-Pub 1996. PMID: 9499823.
267. García-Rayo S, Gúrpide A, Vega F, Brugarolas A. [Spontaneous tumor regression in a patient with multiple myeloma. Report of another case]. Rev Med Univ Navarra 40(3):41-2, 1996. e-Pub 1996. PMID: 9499825.
268. Vega F, Sierrasesumaga L, Panizo A, Diaz L, Foncillas J. Metastasis Pulmonares de Osteosarcoma:Factores pronosticos. Patologia 29:325-331, 1996. e-Pub 1996.
269. Vega F. Pseudomixoma Peritonei. Rev Med Univ Navarra 2:64, 1996. e-Pub 1996.
270. Arias M, Abreu JA, Iglesias A, Longo J, Lecumberri F, Vega F. Primary amyloidosis presenting as renal infarction. Eur-Radiol 6(3):346-8, 1996. e-Pub 1996. PMID: 8798004.
271. Vega F. Adenocarcinoma de Sigma. Rev Med Univ Navarra 40:190, 1996. e-Pub 1996.
272. Vega F, Pardo-Mindan FJ. Carcinoma Difuso Gastrico. Rev Med Univ Navarra 1995 39:84, 1995. e-Pub 1995.
273. Gimeno Ballester J, Ruza-Paz Curbera E, Crespo Cuadrado E, Azcona San Julian C, Vega F, Sierrasesumaga L. Actualizacion de la Hepatitis C. A proposito de un caso. Bol S Vasco-Nav Ped 89:79-85, 1995. e-Pub 1995.
274. Vega F, Pardo-Mindan FJ. Carcinoma Gastrico de Celulas en Anillo de Sello. Rev Med Univ Navarra 39:47, 1995. e-Pub 1995.
275. Vega F, Pardo-Mindan FJ. Quiste Hidatidico Hepatico. Cir Iber Americana 3:62, 1994. e-Pub 1994.
276. Vega F, Pardo-Mindan FJ. Colecistitis Cronica Esclerosante. Rev Med Univ Navarra 39:30, 1994. e-Pub 1994.
277. Vega F, Pardo-Mindan FJ. Carcinoma Ductal Infiltrante de Mama. Cir Iber Americana 3:127, 1994. e-Pub 1994.

Manuals, Teaching Aids, Other Teaching Publications

1. Vega F. Understanding Hodgkin lymphoma. A guide for patients, survivors and loved ones. Lymphoma Research Foundation, 2017.
2. Pardo-Mindan FJ, Sola I, Idoate M, de Alva E, Lozano MD, Panozo A, Vega F, Diaz L, Fernandez J. CD-ROM INTERPAT Interactive Teaching of Anatomic Pathology by Computer, 1999.

Other Articles

1. Medeiros, LJ, Marques-Piubelli, ML, Sangiorgio, VF, Ruiz-Cordero, R, Vega, F, Feldman, AL, Chapman, JR, Clemens, MW, Hunt, KK, Evans, MG, Khoo, C, Lade, S, Silberman, M, Morkowski, JJ, Pina, EM, Mills, DC, Bates, CM, Magno, WB, Sohani, AR, Sieling, BA, O'Donoghue, JM, Bacon, CM, Patani, N, Televantou, D, Turner, SD, Johnson, LL, MacNeill, F, Wotherspoon, A, Iyer, SP, Malpica Castillo, LE, Patel, KP, Xu, J, Miranda, R Corrigendum to “Epstein–Barr-virus-positive large B-cell lymphoma associated with breast implants. Modern Pathology 36(12), 2023. PMID: 37948938.
2. Magistri, M, Happ, LE, Ramdial, JL, Lu, XQ, Stathias, V, Kunkalla, K, Agarwal, N, Jiang, XY, Schürer, S, Dubovy, SR, Chapman, JR, Vega, F, Dave, SS, Lossos, IS Erratum. Cancer Research Communications 3(8):1688, 2023. PMID: 37649813.
3. Safavi, S, Larouche, A, Zahn, A, Patenaude, AM, Domanska, D, Dionne, K, Rognes, T, Dingler, F, Kang, SK, Liu, Y, Johnson, N, Hébert, J, Verdun, RE, Rada, C, Vega, F, Nilsen, H, Noia, JM Erratum. NAR Cancer 3(1), 2021. PMID: 34316697.
4. Greenblatt, SM, Man, N, Hamard, PJ, Asai, T, Karl, D, Martinez, C, Bilbao, D, Stathias, V, Jermakowicz, AM, Duffort, S, Tadi, M, Blumenthal, E, Newman, S, Vu, L, Xu, Y, Liu, F, Schürer, S, McCabe, MT, Kruger, RG, Xu, M, Yang, FC, Tenen, DG, Watts, JM, Vega, F, Nimer, SD Erratum. Cancer cell 35(1):156, 2019. PMID: 30645972.
5. Greenblatt, SM, Man, N, Hamard, PJ, Asai, T, Karl, D, Martinez, C, Bilbao, D, Stathias, V, McGrew-Jermacowicz, A, Duffort, S, Tadi, M, Blumenthal, E, Newman, S, Vu, L, Xu, Y, Liu, F, Schürer, S, McCabe, MT, Kruger, RG, Xu, M, Yang, FC, Tenen, DG, Watts, JM, Vega, F, Nimer, SD Erratum. Cancer cell 34(5):868, 2018. PMID: 30423301.
6. Villada, G, Vega, F Erratum. Blood 129(23):3135, 2017. PMID: 28596440.
7. Agarwal, N, Qu, C, Kunkalla, K, Liu, Y, Vega , F Erratum. Journal of Biological Chemistry 288(27):19647, 2013.
8. Vega, F, Chang, CC, Medeiros, LJ, Udden, MM, Cho-Vega, JH, Lau, CC, Finch, CJ, Vilchez, RA, McGregor, DK, Jorgensen, JL Erratum. Modern Pathology 18(6):873, 2005.
9. Vega, F, Medeiros, LJ Marginal-zone B-cell lymphoma of extranodal mucosa-associated lymphoid tissue type. Advances in anatomic pathology 8(6):313-326, 2001. PMID: 11707622.

Editorials

1. Bueso Ramos CE, Medeiros LJ, Vega. Introduction to the 2013 Workshop of the Society for Hematopathology/European Association for Haematopathology. Am J Clin Pathol 144(1):4-5, 2015. PMID: 26071457.

Abstracts

1. Flerlage J, Eichenauer D, Fuchs M, Hartmann S, Eich H, Savage K, Lo A, Skinnider B, Akhtar S, Rauf M, Maghfoor I, Pinnix C, Steiner R, Milgrom S, Vega F, Alomari M, Zhang X, Collins G, Advani R, Kumar P, Dickinson M, Wirth A, Tsang R, Prica A, Major A, Smith S, Hendrickson P, Kelsey C, Hopkins D, McKay P, Ng A, Koenig J, Constine L, Casulo C, Sakthivel G, Baron J, Plastaras J, Roberts K, Gao S, Alkendi J, Rahbi N, Balogh A, Levis M, Ricardi U, Sridhar A, Torka P, Specht L, Silva R, Shah N, Pickard K, Osborne W, Blazin L, Henry M, Chang I, Smith C, Halperin D, Miall F, Brady J, Mikhaeel G, Brennan B, Penn A, Senchenko M, Volchkov E, Reeves M, Hoppe B, Terezakis S, Talaulikar D, Pepa R, Picardi M, Kirova Y, Fergusson P, Northend M, Hawkes E, Lee D, Doo N, Barraclough A, Opat S, Cheah C, Salvaris R, Ku M, Hamad N, Mutsando H, Tedjaseputra A, Gilbertson M, Marconi T, Viiala N, Palese M, Shankar A, Maurer M, Natkunam Y, Kelly K, Borchmann P, Hoppe R, Binkley M. RADIOTHERAPY IMPROVES PROGRESSION-FREE SURVIVAL FOR STAGE IA NLPHL: A RETROSPECTIVE REPORT FROM THE GLOBAL NLPHL ONE WORKING GROUP (GLOW). ICLM 2025 Lugano, 2025. e-Pub 2025.
2. Russler-Germain D, Li X, Singhal K, Deng Q, Chihara D, Hussein U, Foltz J, Henderson J, Wilson A, Tobin J, Gandhi M, Schmidt E, Nizamuddin I, Dinh T, Sun R, Kesaraju A, Hilton L, Scott D, Vega F, Flowers C, Westin J, Griffith O, Fehniger T, Griffith M, Green M. LARGE B-CELL LYMPHOMA MICROENVIRONMENT ARCHETYPE PROFILES (LYMPHOMAPS) IDENTIFY SUBGROUPS WITH GREATEST BENEFIT FROM CD19 CAR T-CELL THERAPY. 18-ICML Lugano, 2025. e-Pub 2025.
3. Saul EE, Valcarcel B, Ayers AA, Noorani M, Chihara D, Furqan F, Ahmed S, Iyer SP, Neelapu SS, Fayad LE, Hagemeister F, Nze C, Jain P, Wang M, Strati P, Chauhan A, Vega F, Flowers CR, Westin JR. Retreatment with R-CHOP-like Therapy Is Active with Durable Responses in Patients with Late Relapse of Diffuse Large B-Cell Lymphoma. ASH, 2024. e-Pub 2024.
4. Nair R, Duenas DE, Liu J, Prakash R, Zhou C, Koksoy AA, Xu J, McAllen SA, Malpica L, Luthra R, Vega F, Miranda RN, Zhang J, Medeiros L, Haymaker CL, Flowers CR, Neelapu SS, Iyer SP. An Integrated Spatial, Codex, and Genomic Analysis Predicts Responsiveness and Survival in the Phase II Combination of Pembrolizumab and Romidepsin in PTCL. ASH, 2024. e-Pub 2024.
5. Lionel A, Murphy K, Ayers AA, Flowers CR, Patel KP, DiNardo CD, Vega F, Chihara D. Survival Outcomes and Genetic Assessment in Patients with Dual Diagnoses of B-Cell and T-Cell Lymphomas. ASH, 2024. e-Pub 2024.
6. Li X, Singhal K, Deng Q, Chihara D, Russler-Germain DA, Hussein U, Foltz JA, Henderson J, Wilson A, Schmidt E, Nizamuddin IA, Dinh T, Sun R, Kesaraju A, Hilton LK, Scott DW, MBChB, Vega F, Flowers CR, Griffith O, Fehniger TA, Griffith M, Green MR. Comprehensive Characterization and Validation of the Tumor Microenvironment in Patients with Relapsed/Refractory Large B-Cell Lymphoma Identifies Subgroups with Greatest Benefit from CD19 CAR T-Cell Therapy. ASH, 2024. e-Pub 2024.
7. Jain P, Ok CY, Westin JR, Hill HA, Nair R, Iyer SP, Fetooh A, Lee HJ, Ahmed S, Kanagal-Shamanna R, Jelloul FZ, Malpica L, Liu Y, Li Y, Feng L, Badillo M, Thirumurthi S, Deswal A, Iliescu C, Nguyen VQ, Bolshakova AA, Tabakov D, Goldberg MG, Tyshevich A, Vasileva T, Shavronskaya D, Nomie K, Tang G, Patel KP, Vega F, Medeiros L, Flowers CR, Wang M. Acalabrutinib with Rituximab Is Highly Effective First Line Treatment for Older Patients with Mantle Cell Lymphoma. ASH, 2024. e-Pub 2024.
8. Kettlun C, Galvan D, Xu J, Sainz Zuniga TP, Juarez-Casillas S, Diaz Rohena DY, Sahu V, Donoso JA, Zubero A, Rojas-Neira E, Blake D, Henderson J, Green M, Kadia TM, Sampath D, Vega F. Generation of a Patient Derived T-Cell Prolymphocytic Leukemia Xenograft Model to Evaluate Pre-Clinical Treatment with Small Molecule Inhibitors In Vivo. ASH, 2024. e-Pub 2024.
9. Lohray R, Feng L, Huen AO, PharmD, Ogundipe I, Malpica L, Dabaja BS, Dai J, Gunther JR, Hosing C, Miranda RN, Medeiros L, Srour SA, Ramdial J, Vega F, Noorani M, Ayers AA, Fang PQ, Fayad LE, Pinnix CC, Duvic M, Xu J, Flowers CR, Wu SY, Kim K, Torres-Cabala CP, Iyer SP, Nair R. Large Cell Transformation in Mycosis Fungoides & Sezary Syndrome: An Analysis of 445 Cases. ASH, 2024. e-Pub 2024.
10. Kettlun CS, Galvan D, Xu J, Diaz-Rohena D, Pawar V, Sainz Zuniga TP, Sahu V, Casillas SJ, Rojas-Neira E, Henderson J, Aradhya A, Agarwal N, Green M, Kadia T, Sampath D, Vega F. Generation of an In vivo T-Cell Prolymphocytic Leukemia Patient Derived Xenograft Model to Evaluate Clinical Treatment with Small Molecule Inhibitors, 2024. e-Pub 2024.
11. Duenas DE, Marques-Piubelli ML, Vega F. CD70 is Overexpressed in EBV-Positive Diffuse Large B-Cell Lymphoma. USCAP, 2024. e-Pub 2024.
12. Rivera RS, Gonta R, Miranda RN, Quesada AE, Li S, Xu J, Vega F, Medeiros L, Lin P. Can Targeted Next Generation Sequencing Aid in Diagnosis and Subclassification of Marginal Zone Lymphoma Involving Bone Marrow?. USCAP, 2024. e-Pub 2024.
13. Dimopoulos YP, Rivera RS, Medeiros L, Vega F. The Spectrum of B-Cell/Plasma Cell Proliferations in Patients with Nodal T-Follicular Helper Cell Lymphomas. USCAP, 2024. e-Pub 2024.
14. Nwogbo OV, Li S, Miranda RN, Vega F, Medeiros L, Ok CY. TP53-Mutated Mantle Cell Lymphoma shows Distinct Mutational Profiles from TP53-Wild Type Mantle Cell Lymphoma, 2024. e-Pub 2024.
15. Shuyu E, Vega F, Khanlari M, Fang H, Xu J, Li S, Hu S, Wang SA, Medeiros LJ, Wang W. BCL11B Helps to Define T-Lineage in Cases of Lymphoma/Leukemia with a Mixed or Ambiguous Phenotype. USCAP, 2024. e-Pub 2024.
16. Westin, J, Steiner, R, Chihara, D, Ahmed, S, Jain, P, Malpica, L, Iyer, S, Fayad, L, Nair, R, Nastoupil, L, Neelapu, S, Henderson, J, Rodriguez, MA, Hagemeister, FB, Vega, F, Pulsifer, B, Tom, J, Durmic, I, Masand, G, Feng, L, Green, M, Flowers, C, Strati, P. Smart Stop: Lenalidomide, Tafasitamab, Rituximab, and Acalabrutinib Alone and with Combination Chemotherapy for the Treatment of Newly Diagnosed Diffuse Large B-Cell Lymphoma. AMERICAN SOCIETY OF HEMATOLOGY, 2023. e-Pub 2023.
17. Rafei, MD, Basar, MD, Acharya, PhD, Zhang, PhD, Liu, PhD, Mae Moseley, May Daher, MD, Agarwal, MS, PhD, L. Marques-Piubelli, MD, Uprety, Melo Garcia, MD, MS, Shanley, PhD, Banerjee, PhD, Li, MD, PhD, Levi Rosemore, Kumar, PhD, K. Nunez Cortes, MD, Biederstädt, MD, Islam, Kaplan, Hu, Manzar, MD PhD, Lin, MD, PhD, Marin, MD, E. Champlin, MD, Vega, MD, PhD, J. Shpall, MD, Rezvani, MD. Targeting T-Cell Lymphoma Using CD70-Directed Cord Blood-Derived CAR-NK Cells. AMERICAN SOCIETY OF HEMATOLOGY, 2023. e-Pub 2023.
18. Anand Pawar, PhD, Aradhya, Galvan, Borthakur, MD, P. Iyer, MD, Kirschbaum, Blake, PhD, M. Kadia, MD, Sampath, PhD, Vega Francisco MD, PhD. Preclinical Evaluation of T-Cell Prolymphocytic Leukemia Demonstrates Heterogeneous BCL2-Family Dependency That May be Effectively Targeted with Small Molecule Inhibitors. AMERICAN SOCIETY OF HEMATOLOGY, 2023. e-Pub 2023.
19. Zhou, Xu, MD PHD, Prakash, BS, P Torres-Cabala, MD, Chen, PhD, Madduri, PhD, Rao, PhD, Agasthya, PhD, Vega, F, O’Malley, MD, Medeiros, MD, Kumara, PhD, P. Iyer, MD. Developing Deep Learning Pipeline of Whole-Slide Images for Enhanced Diffuse Large B Cell Lymphoma (DLBCL) Subtyping and Outcome Prediction: Leveraging Self-Attention Transformer for Training and Inference. AMERICAN SOCIETY OF HEMATOLOGY, 2023. e-Pub 2023.
20. MD, PhD, Chen, PhD, C. Larson, MS, Bennani, MD, Wallace, MD, B. Allen, L Jaye, MD, B. Cohen, MD, MS, Malpica Castillo, MD, Vega MD, PhD, Ighirami, MD, Mou, MD, Casulo, MD, Mehta-Shah, MD, Martin, MD, J. Maurer, DSc, S. Kahl, MD, S. Lossos, MD, Cerhan, MD, PhD, R. Flowers, MD, M, L. Feldman, MD. Patterns of Care and Impact of Initial Treatment in Peripheral T-Cell Lymphoma: Outcome Analysis from the Lymphoma Epidemiology of Outcomes (LEO) and Molecular Epidemiology Resource (MER) Prospective Cohort Study. AMERICAN SOCIETY OF HEMATOLOGY, 2023. e-Pub 2023.
21. Jain, MD, MBBS, PhD, DM, Young OK, J. Nastoupil, MD, Westin, MD, A Hill, MS, Nair, MD, P. Iyer, MD, Fetooh, MD, Ju Lee, MD, Ahmed, MD, Kanagal-Shamanna, MD, Z Jelloul, Malpica Castillo, M, Liu, PhD, Li, BS, MS, Vargas, Feng, MS, Badillo, Thirumurthi, MD1, Xu, MBBS, PhD, Deswal, MD, MPH, MBBS1, Iliescu, MD, Nguyen, MD, Tang, MD, PhD, P. Patel, MBBS, PhD, Vega, MD, PhD, Medeiros, MD, L. Wang, MD, R. Flowers, MD, MS. Acalabrutinib with Rituximab As First-Line Therapy for Older Patients with Mantle Cell Lymphoma – a Phase II Clinical Trial. AMERICAN SOCIETY OF HEMATOLOGY, 2023. e-Pub 2023.
22. Abro, MD, Maurer, DSc, M. Habermann, MD, Burack, MD, PhD, R. Chapman-Fredricks, MD, B. Cohen, MD, MS, W. Friedberg, MD, MMS, Inghirami, MD, S. Kahl, MD, C. Larson, MS, K. Link, MD, S. Lossos, MD, Martin, MD, J. McDonnell, MD, PhD, J. Nastoupil, MD, M. Riska, Syrbu, MD, PhD, Vega MD, PhD, R. Vij, R. Flowers, MD, MS, R. Cerhan, MD, PhD, L Jaye, MD, L. Feldman, MD. Real-World Impact of Differences in the World Health Organization (WHO) Classification and International Consensus Classification (ICC) Systems on the Diagnosis of Non-Hodgkin Lymphoma: An Analysis from the LEO Cohort Study. AMERICAN SOCIETY OF HEMATOLOGY, 2023. e-Pub 2023.
23. Jain, MD, MBBS, PhD, DM, A Hill, MS, Ok, MD, Nesmalov, PhD, Segodin, Tabakov, PhD, Kotlov, Zemskiy, Belykh, Nomie, PhD, Fetooh, MD, Kanagal-Shamanna, MD, Z Jellou, Tang, MD, PhD, Vega, MD, PhD, Fowler, MD, Flowers, MD, MS, L. Wang, MD. Genomic and Transcriptomic Profiles of Blastoid and Pleomorphic Mantle Cell Lymphoma Are Distinct from Classic Histology Mantle Cell Lymphoma. AMERICAN SOCIETY OF HEMATOLOGY, 2023. e-Pub 2023.
24. Gaulin, MBBS, Jain, MD, MBBS, Nair, MD, Iyer, MD, Ju Lee, MD, Fayad, MD, Feng, MS, Liu, PhD, A Hill, MS, BS, MS1, Ok, MD, Kanagal-Shamanna, MD, Oriabure, MSN, RN, NP, BS, MPAS, MS, Siddiqui, MS, MBBS, PhD, Deswal, MD, Iliescu, MD, Badillo, Li, MD, Ky, Avellaneda, Tang, MD, PhD, Vega, MD, PhD, R. Flowers, MD, MS, L. Wang, MD. Phase II Trial of Ibrutinib in Previously Untreated High-Risk Smoldering Mantle Cell Lymphoma. AMERICAN SOCIETY OF HEMATOLOGY, 2023. e-Pub 2023.
25. Westin, MD, Nair, MD, Fayad, MD, P. Iyer, MD, Malpica, MD, Neelapu, MD, Samaniego, MD, Eric Steiner, MD, Strati, MD, Mathew, Griffith, Nastoupil, MD, Montinez, Alma Rodriguez, M, Hagemeister, Feng, MS, Vega, MD, PhD, R. Flowers, MD, Ahmed, MD7. Nivolumab and Ibrutinib for Treatment of Patients with Refractory or Relapsed Central Nervous System Lymphoma. AMERICAN SOCIETY OF HEMATOLOGY, 2023. e-Pub 2023.
26. M S Binkley M, J E Flerlage J, P Borchmann P, M Fuchs M, S Hartmann S, H T Eich H, K J Savage K, A Lo A, B Skinnider B, S Akhtar S, M S Rauf M, I Maghfoor I, C C Pinnix C, R Steiner R, S A Milgrom S, F Vega, M Alomari M, X Zhang X, G Collins G, R H Advani R, M Metzger M, M Dickinson M, A Wirth A, R Tsang R, A Prica A, A Major A, S Smith S, P G Hendrickson P, C R Kelsey C, D Hopkins D, P McKay P, A Ng A, J Koenig J, L S Constine L, C Casulo C, G Sakthivel G, J Baron J, J P Plastaras J, K B Roberts K, S Gao S, J Al Kendi J, N Al Rahbi N, A Balogh A, M Levis M, U Ricardi U, A Sridhar A, P Torka P, L Specht L, R De Silva R, N Shah N, K Pickard K, W Osborne W, L J Blazin L, M Henry M, I Chang I, C M Smith C, D Halperin D, F Miall F, J Brady J, G Mikhaeel G, B Brennan B, A Penn A, M A Senchenko M, E V Volchkov E, M Reeves M, B Hoppe B, S Terezakis S, D Talaulikar D, R Della Pepa R, M Picardi M, Y Kirova Y, P Fergusson P, M Northend M, A Shankar A, M J Maurer M, Y Natkunam Y, K M Kelly K, D A Eichenauer D, R T Hoppe R. The prognostic impact of clinical factors and immunoarchitectural patterns for nodular lymphocyte-predominant Hodgkin lymphoma: an international study by GLOW. AMERICAN SOCIETY OF HEMATOLOGY, 2023. e-Pub 2023.
27. Elias, A, Marques-Piubelli, M, Nair, R, Prakash, R, Ahmed, S, Malpica, L, Ju Lee, H, Xu, J, Flowers, C, Neelapu, S, Vega, F, Miranda, R, Iyer, S. Prognostic Significance of CD30 Expression and Response to Brentuximab Vedotin in Patients with Angioimmunoblastic T Cell Lymphoma. AMERICAN SOCIETY OF HEMATOLOGY, 2023. e-Pub 2023.
28. Amador, MD, Weisenburger, MD, Gomez, MD, Bouska, PhD, Vega, MD, PhD, R. Cook, MD, PhD, C. Greiner, MS, MD, L. Feldman, MD, S. Jaffe, MD, L. Ondrejka, DO, Ott, MD, Ozkaya, MD, Raess, MD, Rosenwald, MD, J. Savage, MD, MSc, BSc, Slack, MD, Song, MD, Rimsza, MD, Chan, MD, Iqbal, PhD, MSc2. Refining Diagnostic Subtypes of Peripheral T-Cell Lymphoma Using a Multiparameter Approach. AMERICAN SOCIETY OF HEMATOLOGY, 2023. e-Pub 2023.
29. Armitage, BA, Gibson, MD, S de Carvalho, BS MS, Wisner, AA, Y Song, MD, C. Chan, MD, Chapman-Fredricks, MD, Vega MD, PhD, A. Pileri, MD, PhD, de Jager, MD, E Leal, MD, Rimsza, MD. Genomic Stability, DNA Repair and the SKP1-CUL1-F-Box Complex in HIV Associated Diffuse Large B-Cell Lymphoma. AMERICAN SOCIETY OF HEMATOLOGY, 2023. e-Pub 2023.
30. Jain, MD, MBBS, PhD, DM, Ju Lee, MD, Westin, MD, Nastoupil, MD, Fayad, MD, Nair, MD, P. Iyer, MD, Kanagal-Shamanna, MD, Fetooh, MD, Hill, MS, Ok, MD, Chen, BS, MPAS, MS, Oriabure, MSN, RN, NP, Feng, MS, Tang, MD, PhD, Vega, MD, PhD, Badillo, Flowers, MD, L. Wang, MD. Six Years Follow up of Ibrutinib Plus Rituximab (IR) Followed By Short Course R-Hyper CVAD/MTX in Patients (age ≤ 65 years) with Previously Untreated Mantle Cell Lymphoma – Phase-II Window-1 Clinical Trial. AMERICAN SOCIETY OF HEMATOLOGY, 2023. e-Pub 2023.
31. Nahmod K, Thakral B, Wang W, Aakash F, Patel K, Routbort M, Kanagal-Shamanna R, Ok CY, Tang G, Vega F, Medeiros LJ, Wang S, Loghavi S. Bone Marrow Immunophenotype and Genotype Characteristics Assessed by Flow Cytometry and Next Generation Sequencing in 147 Patients with Myeloid Sarcoma. USCAP, 2023. e-Pub 2023.
32. Nwogbo O, San Lucas F, Dang H, Marques-Piubelli ML, Ayers A, Alvarez H, Luthra R, Nastoupil L, Flowers C, Medeiros LJ, Patel K, Vega F. Targeted Sequencing in DLBCL, Clinicopathologic Features and LymphGen Signature: Our Clinical Experience. USCAP, 2023. e-Pub 2023.
33. Kim DH, Jelloul FZ, Loghavi S, Kanagal-Shamanna R, Yin C, Zuo Z, Patel K, Routbort M, Li S, Vega F, Miranda R, Medeiros LJ, Ok CY. Next-Generation Sequencing Identifies Approximately One Third of Mantle Cell Lymphoma Patients with Nuclear Factor-kappa B Pathway Mutations. USCAP, 2023. e-Pub 2023.
34. Hamana Zorilla LG, Lee H, Schmidt J, Kamel S, Bota Rabassedas MN, Sanchez-Espiridion B, Shen L, Wang J, Wistuba I, Solis Soto L, Vega F, Marques-Piubelli ML. Gene Expression Profile as a Therapeutic Biomarker for Classic Hodgkin Lymphoma Treated with Immunotherapy-Based Regimens. USCAP, 2023. e-Pub 2023.
35. Nair R, Ayers A, Nastoupil LJ, Gunther JR, Fayad L, Fowler NH, Miranda RN, Hagemeister FB, Lee HJ, Rodriguez MA, Steiner R, Strati P, Nieto Y, Ramdial JL, Chihara D, Wang ML, Malpica Castillo LE, Saini N, Jain P, Pinnix CC, Dabaja BS, Green MR, Flowers CR, L Jeffrey Medeiros L, Marques-Piubelli ML, Vega F, Noorani M, Ahmed S, Westin J, Neelapu SS, Feng L, Iyer SP. CAR-T Outcomes in Patients with EBV-Positive DLBCL. ASH 2022 Meeting, 2022. e-Pub 2022.
36. Deng Q, Meydan C, Lakra P, Barisic D, Chin CR, Rojas-Neira E, Ravanmehr V, Henderson J, Gou P, El-Mallawany NK, Allen C, Cuglievan B, Vega F, Maso CE, Melnick A, Green MR. Smarca4 (Brg1) Controls Germinal Center B-Cell Development and Is a Haploinsufficient. ASH 2022 Meeting, 2022. e-Pub 2022.
37. Ruan J, Larson MC, Chen Z, N Nora Nora Bennani N, Allen PB, Jaye DL, Cohen JB, Chihara D, Vega F, Inghirami G, Mou E, Casulo C, Mehta-Shah N, Martin P, Maurer MJ, Kahl BS, Lossos IS, Flowers CR, Cerhan JR, Feldman AL. Patterns of Care and Clinical Outcomes in Peripheral T-Cell Lymphomas: The Lymphoma Epidemiology of Outcomes (LEO) and Molecular Epidemiology Resource (LEO-MER) Prospective Cohort Study. ASH 2022 Meeting, 2022. e-Pub 2022.
38. Marques-Piubelli ML, Dueñas D, Qiu L, Nahmod K, Cho JH, M, Jiang M, McAllen S, Solis Soto LM, Steiner R, Pinnix CC, Wistuba II, Parra ER, Vega F. EOMES+ Tr1-like Cells Are Enriched in Areas of NLPHL Group II (Patterns D to F) Supporting the Role of Tregs in Disease. ASH 2022 Meeting, 2022. e-Pub 2022.
39. Agbedia OO, Prakash R, Xu J, Becnel MR, Nair R, Steiner RE, Feng L, Lee HJ, Strati P, Ahmed S, Parmar S, Nieto Y, Hosing C, Westin J, Nastoupil LJ, Samaniego F, Fowler NH, Saini N, Khouri IF, Im JS, MD, Fayad L, Jain P, Wang ML, Miranda RN, Vega F, Medeiros J, Oki Y, Flowers CR, Neelapu SS, Iyer SP. Updated Results of an Investigator-Initiated Phase II Study of Pembrolizumab and Romidepsin for Patients with Relapsed or Refractory T-Cell Lymphoma (TCL) with Survival Analysis. ASH 2022 Meeting, 2022. e-Pub 2022.
40. Nze C, Andersen CR, Ayers A, Westin J, Wang ML, Iyer SP, Ahmed S, Pinnix CC, Vega F, McNeil L, Nguyen L, Nastoupil LJ, Flowers CR. Impact of Patient Demographics and Neighborhood Socioeconomic Variables on Clinical Trial Participation Patterns for Non-Hodgkin Lymphoma at a Major Academic Institution. ASH 2022 Meeting, 2022. e-Pub 2022.
41. Jai P, Ok CY, Fetooh A, Kanagal-Shamanna R, Jelloul FZ, Hill H, Floyd K, Loghavi S, Zuo Z, C Cameron Yin C, Routbort M, Tang G, Ahmed S, Malpica Castillo LE, Siddiqui A, Chen W, Oriabure O, Badillo M, Steiner RE, Iyer SP, Lee HJ, Luthra R, Vega F, Flowers CR, Medeiros J, Wang ML, Patel KP, Fowler NH, Nair R. Mutation Spectrum, Characteristics and Impact of Mutation Profiling on Prognosis, Outcome and Treatment Responses in Patients (pts) with Mantle Cell Lymphoma. ASH 2022 Meeting, 2022. e-Pub 2022.
42. Kizhakeyil A, Ghosh S, Rojas-Neira E, Deng Q, Henderson J, Showell J, Melnick A, Béguelin W, Vega F, Nastoupil LJ, Green MR. DTX1 Controls Germinal Center B-Cell Development and Lymphomagenesis. ASH 2022 Meeting, 2022. e-Pub 2022.
43. Agarwal N, Aradhya A, Marques-Piubelli ML, Solis Soto LM, Bilbao D, Landgraf R, Ravanmeh V, Henderson J, Green MR, Davis E, Vega F. B-Cell Receptor Signaling Modulates Cholesterol Biosynthesis in Diffuse Large B-Cell Lymphoma. ASH 2022 Meeting, 2022. e-Pub 2022.
44. Cherng HJ, Alig S, Oki Y, Nastoupil LJ, Fayad L, Neelapu SS, Turturro F, Hagemeister FB, Rodriguez MA, Lee HJ, McDonnell T, Flowers C, Vega F, Green MR, Alizadeh AA, Davis RE, Westin J. Long-term outcomes and circulating tumor DNA analysis from a phase I/II study of lenalidomide and obinutuzumab with CHOP for newly diagnosed diffuse large B-cell lymphoma. Journal of Clinical Oncology 40(16_suppl):7553-7553, 2022. e-Pub 2022.
45. Humphries CM, Ohgami RS, Young KH, Wang B, Vega F, L Marques-Piubelli ML, Zhao X, Rubenstein J, His ED. Clinicopathologic Features of Primary Central Nervous System (PCNS) Anaplastic Large Cell Lymphoma (ALCL): A Multicenter Study. Los Angeles USCAP. USCAP, 2022. e-Pub 2022.
46. Latchmansingh K, Wang X, Verdun RE, Vega F, M James You M, Lossos IS, Chapman JR. LMO2 Expression is Frequent in T-lymphoblastic Leukemia and Correlates with Survival, Regardless of T-cell Stage. Los Angeles USCAP. USCAP, 2022. e-Pub 2022.
47. Kim DH, Li S, Kanagal-Shamanna R, Miranda RN, Vega F, L Jeffrey Medeiros L, Ok CY. Next-generation Sequencing Revealed Frequent TP53 mutation in Mantle Cell Lymphoma with Enhancer of Zeste Homolog 2 (EZH2) Expression. Los Angeles USCAP. USCAP, 2022. e-Pub 2022.
48. Wang X, Garces SA, Fang H, Qiu L, Wang W, Loghavi S, Jelloul FZ, Vega F, Miranda RN, Muzzafar T, Manning JT, Yambayev I, Burack R, Evans AG, Khoury JD, L Jeffrey Medeiros L, Hussein SE. Nodular Lymphocyte Predominant Hodgkin Lymphoma with Nodular Sclerosis-Like Features: An Underrecognized Variant with a Strong Association with Pattern D. Los Angeles USCAP. USCAP, 2022. e-Pub 2022.
49. Wang M, Jain P, Lee HJ, Ok CY, Hill H, Navsaria L, Kanagal-Shamanna R, Malpica-Castillo L, Nair R, Iyer SP, Samaniego F, Chen W, Oriabure1 O, Feng L, Thirumurthi S, Santos D, Tang G, Vega F, Li S, Avellaneda1 M, Badillo M, Flowers CR. Ibrutinib Plus Rituximab and Venetoclax (IRV) Followed By Risk-Stratified Observation or Short Course R-Hypercvad/MTX in Young Patients with Previously Untreated Mantle Cell Lymphoma – Phase-II Window-2 Clinical Trial. 2021 ASH Annual Meeting, 2021. e-Pub 2021.
50. Choudhary RK, Jones RJ, Kuiatse I, Wang H, Vega F, Bouska AC, Lone WG, Iqbal J, Orlowski RZ. A Novel Antibody Drug Conjugate (ADC) Targeting Cell Surface Heat Shock Protein 70 (csHSP70) Is Active Against Pre-Clinical Models of Peripheral T-Cell Lymphoma (PTCL). 2021 ASH Annual Meeting, 2021. e-Pub 2021.
51. Malpica-Castillo L, Feng L, Xu J, Nair R, Elias A, Jain P, Chihara D, Steiner R, Fayad L, Samaniego F, Ahmed S, Fowler NH, MD1, Nastoupil L, Srour SA, Nieto Y, Hosing C, Miranda RN, Vega F, Pinnix CC, Gunther JR, Fang P, Wu S, Dabaja BS, Medeiros J, Wang M, Neelapu SS, Flowers CR, Iyer SP. Long Term Outcome Patterns and Risk Factors for Early Mortality and Disease Progression in ALK-Positive Anaplastic Large Cell Lymphoma. 2021 ASH Annual Meeting, 2021. e-Pub 2021.
52. Jain P, Nomie K, Segodin V, Egorov E, Yao Y, Navsaria L, Hill H, Kotlov N, Kanagal-Shamanna R, Ok CY, Vega F, Li S, Che Y, Li Y, Svekolkin V, Bagaev A, Frenkel F, Attaulakhanov R, Fowler NH, Flowers CR, Wang M. Immune-Depleted Tumor Microenvironment Signature Is Associated with BTK Inhibitor Resistance in Mantle Cell Lymphoma. 2021 ASH Annual Meeting, 2021. e-Pub 2021.
53. Marques-Piubelli ML, Parra ER, Feng L, Gallardo M, Soto LS, Wistuba II, Flowers CR, Neelapu SS, Vega F, Strati P. Sirpα and CSF1R Positive Tissue Macrophages Are Increased in Patients with Follicular Lymphoma Who Relapse after Frontline Lenalidomide and Rituximab. 2021 ASH Annual Meeting, 2021. e-Pub 2021.
54. Nair R, Deen N, Ahmed S, Miranda RN, Fowler NH, Fayad L, Steiner RE, Hagemeister FB, Rodriguez MA, Lee HJ, Strati P, Malpica-Castillo L, Chihara D, Jain P, Gunther JR, MD, Flowers CR, L Jeffrey Medeiros L, Nieto Y, Ramdial JL, Neelapu SS, Nastoupil L, Green MR, Wang M, Vega F, Feng L, Iyer SP, Westin JR. Outcome of Patients with T- Cell Histiocyte Rich B Cell Lymphoma: Single Institution Series. 2021 ASH Annual Meeting, 2021. e-Pub 2021.
55. Chapman J, Bouska A, Zhang W, Alderuccio J, Lossos I, Yi S, Chan W, Vega F, Song J. Mutational Differences Between EBV-Negative and EBV-Positive HIV-Associated Diffuse Large B-cell Lymphomas. USCAP, 2021. e-Pub 2021.
56. Poveda J, Cassidy D, Zhou Y, Alderuccio J, Lossos I, Vega F, Chapman J. Upregulation of Germinal Center Markers by Extranodal Marginal Zone Lymphoma in Colonized Follicles, a Diagnostic Pitfall with Follicular Lymphoma. USCAP, 2021. e-Pub 2021.
57. Jain P, Tang G, Yin C, Ok C, Navsaria L, Badillo M, Chen W, Li Y, Che Y, Yang L, Oriabure O, Nogueras Gonzalez G, Westin J, Nastoupil L, Ahmed S, Nair R, Thirumurthi S, Li S, Kanagal-Shamanna R, Vega F, Flowers C, Wang M. Complex Karyotype Is a Significant Predictor for Worst Outcomes in Patients with Mantle Cell Lymphoma (MCL) treated with BTK Inhibitors – Comprehensive Analysis of 396 Patients. ASH Annual Meeting (Virtual), 2020. e-Pub 2020.
58. Jain P, Zhang S, Kanagal-Shamanna R, Navsaria L, Ok C, Tang G, Yin C, Badillo M, Chen W, Oriabure O, Lee H, Westin J, Nastoupil L, Moghrabi O, Che Y, Samaniego F, Ahmed S, Nair R, Li S, Vega F, Flowers C, Wang L, Wang M. Outcomes of Acalabrutinib Failures in Relapsed Mantle Cell Lymphoma. ASH Annual Meeting (Virtual), 2020. e-Pub 2020.
59. Srour S, Xu J, Al-Juhaishi T, Steiner R, Ensor J, Ahmed S, Parmar S, Strati P, Nastoupil L, Nieto Y, Hosing C, Lee H, Westin J, Fowler N, Fayad L, Dabaja B, Pinnix C, Gunther J, Fang P, Samaniego F, Jain P, Champlin R, Khouri I, Wang, Miranda R, Vega F, Neelapu S, Flowers C, Iyer S. Retrospective Review of Prognostic and Predictors Markers in Newly Diagnosed Angioimmunoblastic T Cell Lymphoma at UT MD Anderson Cancer Center. ASH Annual Meeting (Virtual), 2020. e-Pub 2020.
60. Jain P, Yao Y, hao S, Liu Y, Hill H, Che Y, Li Y, Jordan A, McIntosh J, Lee H, Steiner R, Samaniego F, Westin J, Nastoupil L, Nair R, Ahmed S, Ok C, Kanagal-Shamana R, Oriabure O, Xu G, Chen W, Moghrabi O, McClain C, Badillo M, Thirumurthi S, Santos D, Iliescu C, Yin C, Li S, Tang G, Vega F, Neelapu S, Flowers C, Wang L, Wang M. Combination of Ibrutinib with Rituximab (IR) In Previously Untreated Older Patients with Mantle Cell Lymphoma (MCL) – a Phase II Clinical Trial. ASH Annual Meeting (Virtual), 2020. e-Pub 2020.
61. Jain P, Kanagal-Shamanna R, Navsaria L, Ok C, Hill H, Jung D, Nogueras Gonzalez G, Lee H, Nair R, Ahmed S, Steiner R, Tang G, Li S, Patel K, Thirumurthi S, Tinsu P, Xu G, Vega F, Flowers C, Wang M. Comprehensive Analysis of Factors Predictive for Time to Transformation and Risk of Transformation in Patients (pts) with Mantle Cell Lymphoma. ASH Annual Meeting (Virtual), 2020. e-Pub 2020.
62. Strati P, Samaniego F, Gallardo M, Noorani M, Hagemeister F, Westin J, Lee H, Rodriguez M, Neelapu S, Gunther J, Kanagal-Shamanna, R, Vega F, Fowler N, Flowers C, Nastoupil L. Treatment and Outcome of Patients with Follicular Lymphoma Relapsed or Progressed after Frontline Lenalidomide and Rituximab. ASH Annual Meeting (Virtual), 2020. e-Pub 2020.
63. Mas MG, Man N, Karl D, Martinez C, Duffort S, Itonga H, Mookhtiar A, Bilbao D, Kunkalla K, Valencia A, Collings C, Kadoch C, Vega F, Kogan S, Nimer S. The Baf Subunit Dpf2 Regulates Resolution of Inflammation By Controlling Macrophage Differentiation Transcription Factor Networks. ASH Annual Meeting (Virtual), 2020. e-Pub 2020.
64. Srour S, Xu J, Al-Juhaishi T, Steiner R, Ensor J, Ahmed S, Parmar S, Strati P, Nastoupil L, Nieto Y, Hosing C, Lee H, Westin J, Fowler N, Fayad L, Dabaja B, Pinnix C, Junther J, Fang P, Amaniego F, Jain P, Champlin R, Khouri I, Wang M, Miranda R, Vega F, Neelapu S, Flowers C, Iyer S. Hodgkin Lymphoma and T/NK Cell Lymphoma – Clinical Studies: Poster I. Retrospective Review of Prognostic and Predictors Markers in Newly Diagnosed Angioimmunoblastic T Cell Lymphoma at UT MD Anderson Cancer Center. ASH Annual Meeting (Virtual), 2020. e-Pub 2020.
65. Gouni S, Strati P, Westin J, Nastoupil L, Steiner R, Nair R, Fayad L, Neelapu S, Landgraf R, Bilbao D, Vega F, Agarwal N. Aggressive Lymphoma (Diffuse Large B-Cell and Other Aggressive B-Cell Non-Hodgkin Lymphomas) – Results from Retrospective/Observational Studies: Poster III. Use of Medium Potency Statins Is Associated with Improved Outcomes after Frontline RCHOP in Patients with Diffuse Large B-Cell Lymphoma (DLBCL). ASH Annual Meeting (Virtual), 2020. e-Pub 2020.
66. Jain P, Yao Y, hao S, Liu Y, Hill H, Che Y, Li Y, Jordan A, McIntosh J, Lee H, Steiner R, Samaniego F, Westin J, Nastoupil L, Nair R, Ahmed S, Ok C, Kanagal-Shamana R, Oriabure O, Xu G, Chen W, Moghrabi O, McClain C, Badillo M, Thirumurthi S, Santos D, Iliescu C, Yin C, Li S, Tang G, Vega F, Neelapu S, Flowers C, Wang L, Wang M. Mantle Cell, Follicular, and Other Indolent B-Cell Lymphoma – Clinical Studies: Poster II. Combination of Ibrutinib with Rituximab (IR) In Previously Untreated Older Patients with Mantle Cell Lymphoma (MCL) – a Phase II Clinical Trial. ASH Annual Meeting (Virtual), 2020. e-Pub 2020.
67. Chin CK, Cheah CY, Jain P, E Fayad NHFL, Westin JR, Rodriguez MA, Neelapu SS, Hagemeister FB, L Jeffrey Medeiros L, Vega F, Samaniego F, Flowers CR, Nastoupil LJ. Clinicopathologic features & outcomes of de novo transformed indolent lymphoma. J Clin Oncol 38, 2020. e-Pub 2020.
68. Martin G, Man N, Karl D, Martinez C, Duffort S, Itonaga H, Mookhtiar A, Bilbao D, unkalla K, Valencia A, Collings C, Kadoch C, Vega F, Kogan S, Nimer S. Disordered Gene Expression in Hematologic Malignancy, including Disordered Epigenetic Regulation: Poster III. The Bf Subunit Dpf2 Regulates Resolution of Inflammation By Controlling Macrophage Differentiation Transcription Factor Networks. ASH Annual Meeting (Virtual), 2020. e-Pub 2020.
69. Iyer S, Xu J, Becnel M, Nair R, Steiner R, Feng L, Lee H, Strati P, Ahmed S, Parmar S, Nieto Y, Hosing C, Westin J, Nastoupil L, Vo A, Samaniego F, Fowler N, Saini N, Khouri I, Jain P, Fayad L, Wang M, Miranda R, Vega F, Flowers C, Neelapu S. A Phase II Study of Pembrolizumab in Combination with Romidepsin Demonstrates Durable Responses in Relapsed or Refractory T-Cell Lymphoma (TCL). ASH Annual Meeting (Virtual), 2020. e-Pub 2020.
70. Gouni S, Strati P, Westin J, Lastoupil L, Steiner R, Nair R, Fayad L, Neelapu S, Landgraf R, Bilbao D, Vega F, Agarwal N. Use of Medium Potency Statins Is Associated with Improved Outcomes after Frontline RCHOP in Patients with Diffuse Large B-Cell Lymphoma (DLBCL). ASH Annual Meeting (Virtual), 2020. e-Pub 2020.
71. Lyapichev K, Bah I, Routbort M, Jorgensen J, Vega F, L Jeffrey Medeiros L, Wang S. Improved Blood Staging of Mycosis Fungoides/Sezary Syndrome (MF/SS) via the Use of ICCS Immunophenotyping Method for Aberrant T-cell Quantitation. USCAP, 2020. e-Pub 2020.
72. Jain P, Tang G, Yin C, Ok C, Navsaria L, Badillo M, Chen W, Li Y, Che Y, Liu Y, Oriabure O, Nogueras Gonzalez G, Westin J, Nastoupil L, Ahmed S, Nair R, Thirumurthi S, Li S, Kanagal-Shamana R, Vega F, Flowers C, Wang M. Mantle Cell, Follicular, and Other Indolent B-Cell Lymphoma-Clinical Studies: Poster I. Complex Karyotype Is a Significant Predictor for Worst Outcomes in Patients with Mantle Cell Lymphoma (MCL) Treated with BTK Inhibitors – Comprehensive Analysis of 396 Patients. ASH Annual Meeting (Virtual), 2020. e-Pub 2020.
73. Wang M, Jain P, Yao Y, Liu Y, Shao S, Hill H, Moghrabi O, Lee H, Samaniego F, Westin J, Nastoupil L, Kanagal-Shamanna R, Ok C, Chen W, Oriabure O, Che Y, Li Y, Feng L, Nogueras Gonzalez G, Xu G, Wagner-Bartak N, Thirumurthi S, Santos D, Tang G, Vega F, Yin C, Avellaneda M, Badillo M, Flowers C, Wang L. Ibrutinib Plus Rituximab (IR) Followed By Short Course R-Hypercvad/MTX in Patients (age </=65 years) with Previously Untreated Mantle Cell Lymphoma – Phase-II Window-1 Clinical Trial. ASH Annual Meeting (Virtual), 2020. e-Pub 2020.
74. Agarwal N, Kunkalla K, Bilbao D, Landgraf R, Vega F. Novel role of RAFT-associated smoothened (SMO) in AKT signal regulation in diffuse large B cell lymphoma. ASH 2019, Orlando FL 134, 2019. e-Pub 2019.
75. White K, Cassidy D, Algashaamy K, Iakymenko O, Sanchez S, Ikpatt O, Vega F, Chapman J. Cyclin D1 Expression in Prolymphocytic Transformation of Marginal Zone Lymphomas. USCAP 32, 2019. e-Pub 2019.
76. Sanchez S, Ali R, Weinreb N, Osorio N, Cassidy D, White K, Chapman J, Vega F, Ikpatt O. Gaucher disease and associated plasma cell myeloma: A diagnostic challenge. USCAP 32, 2019. e-Pub 2019.
77. Cassidy D, White K, Kwon D, Casas C, Sanchez S, Ikpatt O, Chapman J, Vega F. Comparison between Next Generation Sequencing (NGS) and FISH in the Detection of Rearrangements in Large B-cell Lymphomas (LBCLs). USCAP 32, 2019. e-Pub 2019.
78. Oishi N, Dasari S, Jacobs H, Syrbu S, Chapman J, Vega F, Sidhu J, Clemens M, Medeiros LJ, Miranda R, Feldman A. Molecular Profiling Reveals Hypoxia-related Biomarkers and Therapeutic Targets in Breast Implant-associated Anaplastic Large Cell Lymphoma. USCAP 32, 2019. e-Pub 2019.
79. Drakos E, Li L, Bilbao D, Leventaki V, Farrajota Neves Da Silva P, Atsaves V Medeiros LJ, Vega F, Schatz JH, Claret F, Rassidakis G. NPM-ALK upregulates Jab1/CSn5 through STAT3 activation in anaplastic large cell lymphoma: a novel function of NPM-ALK that contributes to PD1/PDL1 immune checkpoint regulation. ASH 2019, Orlando FL, 2019. e-Pub 2019.
80. Flowers C, Link B, Nastoupil L, McDonnell T, Kahl B, Vij K, Casulo C, Friedberg J, Burack R, Lossos I, Thompson C, Yost K, Vega F, Syrbu S, Martin P, Leonard J, Inghirami G, Bernal-Mizrachi L, Mann K, Allmer C, Lunde L, Maurer M, Slager S, Habermann T, Jaye D, Feldman A, and Cerhan JR. The Lymphoma Epidemiology of Outcomes (LEO) Cohort Study Reflects the Demographics and Subtypes of Patients Diagnosed with Non-Hodgkin Lymphoma in the United States. Blood 132, 2018. e-Pub 2018.
81. Magistri M, Happ L, Ramdial J, Kunkalla K, Dubovy SR, Chapman JR, Vega F, Dave S, and Lossos I. Genetic Landscape of Ocular Adnexa Extranodal Marginal Zone Lymphoma. Blood 132, 2018. e-Pub 2018.
82. Tan Y, Mackrides N, Kim JH, Yi S, Gong K, White K, Ikpatt O, Chang WC, Chapman J, Vega F. Mutational Profile of HIV-Related Diffuse Large B-Cell Lymphoma. USCAP 31:559, 2018. e-Pub 2018.
83. Mackrides N, Chapman J, Larson M, Feldman A, Lossos I, Ikpatt O, Tan Y, Syrbu S, Ansell S, Habermann T, Link B, Cerhan J, Vega F. Prevalence, Clinical Characteristics and Prognosis of EBV-Positive Follicular Lymphoma. USCAP 31:537, 2018. e-Pub 2018.
84. Agarwal N, Kunkalla K, Sanchez S, Mackrides, N, Tan Y, Vaghefi A, Chapman J, Ikpatt O, Juskevicius D, Tzankov A, Landgraf R, Vega F. Upregulation and Glycosylation of Smoothened (SMO) Contributes to Doxorubicin (DXR) Resistance in Diffuse Large B-Cell Lymphoma. USCAP, 2018. e-Pub 2018.
85. Cinar M, Rong HR, Chineke I, Jr LA, Chapman-Fredricks JR, Vega F, Gunthel CJ, Love C, Mosunjac M, Flowers C, Dave S, Lossos I, and Bernal-Mizrachi L. Genetic Analysis of Plasmablastic Lymphomas in HIV (+) Patients Reveals Novel Driver Regulators of the Noncanonical NF-Κb Pathway. ASH Annual Meeting, 2018. e-Pub 2018.
86. Verdun R, Parvin S, Labrada A, Santiago GE, E3* C, Eden S, Shlomzion A, Yu Z, Sanchez-Garcia I, Vega F, Chapman-Fredricks J, S Lossos AI. LMO2 Facilitates Synthetic Lethality after PARP Inhibition (PARPi) in Diffuse Large B-Cell Lymphoma (DLBCL). ASH Annual Meeting, 2018. e-Pub 2018.
87. Rajan SS, Li L, Kunkalla K, Amin AD, Agarwal N, Vega F, Schatz JH. CRISPR/Cas9 Generation of Npm1-Alk in Transplantable Murine Hematopoietic Stem Cells Accurately Models ALK-Positive Lymphoma in Recipients. ASH Annual Meeting, 2018. e-Pub 2018.
88. Shuai W, Wu R, Tan Y, Mackrides, N, Alderuccio J, Ikpatt O, Vega F, Chapman J. Primary Bone Diffuse Large B-Cell Lymphoma. USCAP, 2018. e-Pub 2018.
89. Cinar M, Rong HR, Chineke I, Jr LA, Chapman-Fredricks JR, Vega F, Gunthel CJ, Love C, Mosunjac M, Flowers C, Dave S, Lossos I, and Bernal-Mizrachi L. Genetic Analysis of Plasmablastic Lymphomas in HIV (+) Patients Reveals Novel Driver Regulators of the Noncanonical NF-Κb Pathway. ASH Annual Meeting, 2018. e-Pub 2018.
90. Bradley TJ, Monge J, Talati C, Algaze SD, Vaupel CA, Chapman JR, Vega F, Hall J, Lancet JE, Padron E, Swords R, Watts JM. Mutational Frequency in Hispanic and Non-Hispanic Patients with Acute Myeloid Leukemia (AML): Updated Analysis of 227 Patients. Blood 130, 2017. e-Pub 2017.
91. Agarwal N, Kunkalla K, Sanchez S, Vaghefi A, Juskevicius D, Tzankov A, Verdun RE, Landgraf R, Vega F. Upregulation of Alternatively Glycosylated Smoothened (SMO) Is Involved in Doxorubicin (DXR) Resistance in Diffuse Large B-Cell Lymphoma. Blood 130, 2017. e-Pub 2017.
92. Qu C, Vaghefi A, Kunkalla K, Chapman JR, Liu Y, Blonska M, Alderuccio JP, Bernal-Mizrachi L, Lossos IS, Landgraf R, Vega F. Smoothened Stabilizes and Protects TRAF6 from Proteosomal Degradation: A Novel Non-Canonical Role of Smoothened with Implications in Lymphoma Biology. Blood 130, 2017. e-Pub 2017.
93. Chapman J, Vega F, Moul A, Khanlari M, Poveda JC, Villada G, Ikpatt OF, Geyer JT, Orazi A. Myeloid neoplasms with morphologic and molecular features intermediate between PMF and CMML. USCAP 30:341A, 2017. e-Pub 2017.
94. Kerr DA, Vega F, Rosenberg AE. Fibroblastic reticular cell tumor (cytokeratin-positive interstitial reticulum cell tumor): A series of 6 cases with emphasis on extra-nodal presentations. USCAP 30:18A, 2017. e-Pub 2017.
95. Haghefi A, Agarwal NK Kunkalla K, Kim CH, Tjendra Y, Landgraf R, Vega F. Role of SMO in the activation of PI3k/AKT signaling in DLBCL. USCAP, 2017. e-Pub 2017.
96. Khanlari M, Sanchez S, Campuzano-Zuluaga G, Ramos JC, Cho-Vega JH, Vega F, Chapman J. Adult T-cell leukemia/lymphoma (ATLL): A mimicker of other most common T cell neoplasms. USCAP, 2017. e-Pub 2017.
97. Monge J, Vaupel C, Swords RT, Bradley T, Chapman R, Gunaratne N, Chapman JR, Vega F, Padron E, Vargas F, Hall J, Watts J. Mutational frequency in Hispanics vs non-hispanic patients with acute myeloid leukemia. Blood, 2016. e-Pub 2016.
98. Fisher OG, Fernandez MP, Vega F, Dubovy SR. Intraocular extramedullary hematopoiesis: a clinicopathologic case series. Association for research in vision and ophthalmology. Investigate Ophthalmology & Visual Science, 2016. e-Pub 2016.
99. Tjendra Y, Agarwal NK, Kunkalla K, Hwa KC, Gupta A, Chapman J, Torres A, Alderuccio J, Chen SX, Kwon D, Vega F. Significance of Expression of SMO in Diffuse Large B-Cell Lymphoma. USCAP 29:379A, 2016. e-Pub 2016.
100. Gajzer DC, Tjendra Y, Kunkalla K, Kim CH, Ikpatt OF, Chapman J, Sanchez S, Yang G, Kwon D, Vega F, Agarwal NK. Clinical and Biological Significance of GLI1 Expression in Diffuse Large B-Cell Lymphoma. USCAP 29:345A, 2016. e-Pub 2016.
101. Moul A, Tan Y, Hijazi N, Sanchez S, Ikpatt OF, Chapman J, Vega F. Double-Hit Lymphomas with BCL6 / MYC Translocations are Clinicopathologically Different from Those with IgH-BCL2 / MYC and from Triple-Hit Lymphomas. USCAP, 2016. e-Pub 2016.
102. Mackrides N, Maque-Acosta Y, Moul A, Campuzano-Zuluaga G, Vega F, Chapman J. CD20 Negative Nodular Lymphocyte Predominant Hodgkin Lymphoma. USCAP, 2016. e-Pub 2016.
103. Tan Y, Moul E, Gupta A, White KJ, Fan YS, Vega F, Chapman J. HIV-Associated Diffuse Large B-Cell Lymphoma has a disproportionate rate of MYC / BCL6 double translocations. USCAP, 2016. e-Pub 2016.
104. Mackrides N, Maque-Acosta Y, Moul A, Campuzano-Zuluaga G, Natkunam Y, Vega F, Chapman J. EBV-Positive Follicular Lymphoma: Another Age-Related Lymphoma With Aggressive Clinical Features?. USCAP, 2016. e-Pub 2016.
105. Watts J, Perez A, Vargas F, Fan YS, Weismman A, Rodriguez A, Lopez O, Vega F, Swords RT, Zelent A. The Novel Translocation t(4;15)(q31;q22) in AML Is Associated with a Proliferative Phenotype in the Presence of All-Trans Retinoic Acid (ATRA). ASH Annual Meeting, 2016. e-Pub 2016.
106. Azzam D, Henry Volmar C, Ali Hassan A, Perez A, Watts JM, Vargas F, Elias R, Vega F, Zelent A, Cogle C, Wahlestedt C, Swords RT. A patient-specific Ex vivo screening platform for personalized acute myeloid leukemia (AML) therapy. Blood 126(23), 2015. e-Pub 2015.
107. Agarwal NK, Kim CH, Kunkalla K, Tang G, Tjendra Y, Liu Y, Qu C, Vega F. Smoothened (SMO) is an adaptor protein that recruits TRAF6 and phospholipase C gamma 2 (PLCg2) to enhance the activation of NF-kB signaling pathway. Blood 126(23), 2015. e-Pub 2015.
108. Moul A, Teomete U, Ikpatt F, Chapman J, Vega F. HHV8 positive multicentric Castleman disease in an HIV negative patient. 2015 Workshop of the Society for Hematopatholohy/European Association for Haematopathology, 2015. e-Pub 2015.
109. Ruiz‐Cordero R, Moul A, Ikpatt F, Chapman J, Vega F. Unusual Immunophenotypic variant of extracaviatry/solid primary effusion lymphoma expressing IgM. 2015 Workshop of the Society for Hematopatholohy/European Association for Haematopathology, 2015. e-Pub 2015.
110. Zhou X Rosenblatt J; Vega F; Cho-Vega JH. Selection and Rapid Proliferation of an Aggressive Transformed Mycosis Fungoides Clone in a Patient with Classic Mycosis Fungoides and Invasive Ductal Carcinoma Treated with Cytotoxic Chemotherapy. 23rd World Congress of Dermatology, 2015. e-Pub 2015.
111. Agarwal NK, Kunkalla K, Kin CH, Vega F. The Inhibitor of NF-kB Kinase, IKKβ, Regulates the Stability of the Hedgehog Transcription Factor GLI1. USCAP, 2015. e-Pub 2015.
112. Agarwal NK, Kunkalla K, Kin CH, Vega F. The Inhibitor of NF-kB Kinase, IKKβ, Regulates the Stability of the Hedgehog Transcription Factor GLI1. USCAP, 2015. e-Pub 2015.
113. Deutsch Yehuda E, Campuzano-Zuluaga G, Salzberg M, Gomez Arteaga A, Watts JM, Chapman-Fredricks JR, Ikpatt OF, Vega F, Swords RT. Clinical Utility of Morphological Evaluation of Day 14 Bone Marrow Biopsies in Acute Myeloid Leukemia Patients Undergoing Standard Induction Chemotherapy: Time to Change Practice?. ASH Annual Meeting, 2014. e-Pub 2014.
114. Agarwal NK, Kunkalla K, Kin CH, Vega F. Smoothened, hedgehog transducer, contributes to activate NF-kB pathway in diffuse large B cell lymphoma through stabilization of the E3 ligase TRAF6. 15th Annual Zubrod Memorial Lecture and Cancer Research Poster Session, 2014. e-Pub 2014.
115. Agarwal NK, Kunkalla K, Hawke DH, Liu Y, Qu C, Vega F. The inhibitor of NF-ĸB kinase, IKKβ, regulates the stability of GLI1 transcription factor. AACR Annual Meeting, 2014. e-Pub 2014.
116. Agarwal NK, Kunkalla K, Kin CH, F &. Smoothened, Hedgehog Transducer, Contributed to activate NF-KB pathway in diffuse large B cell lymphoma through stabilization of TRAF6. 2014 ASH Meeting on Lymphoma Biology, 2014. e-Pub 2014.
117. Blieden C, Zhou X, Amini S, Vega F, Cho-Vega JH. Cutaneous plasmablastic plasma cell myeloma with MYC gene amplification after antilogous stem-cell transplantation. 51st Annual Meeting of the American Society of Dermatopathology, 2014. e-Pub 2014.
118. Agarwal NK, Kunkalla K, Kin CH, Lossos I, Vega F. The Inhibitor of NF-KB Kinase, IKKβ Regulates the Transcriptional Activity of GLI1 By Blocking Its Proteasomal Degradation. ASH Annual Meeting, 2014. e-Pub 2014.
119. Agarwal NK, Kunkalla K, Hawke DH, Liu Y, Qu C, Vega F. The inhibitor of NF-ĸB kinase, IKKβ, regulates the stability of GLI1 transcription factor. AACR Annual Meeting, 2014. e-Pub 2014.
120. Agarwal NK, Kunkalla K, Kin CH, Lossos I, Vega F. The Inhibitor of NF-KB Kinase, IKKβ Regulates the Transcriptional Activity of GLI1 By Blocking Its Proteasomal Degradation. ASH Annual Meeting, 2014. e-Pub 2014.
121. Agarwal NK, Kunkalla K, Hawke DH, Liu Y, Qu C, Vega F. Transcriptional Regulation Of GLI1, Potential New Therapeutic Target For Diffuse Large B-Cell Lymphoma. Blood 122(21), 2013. e-Pub 2013.
122. Marques-Piubelli ML, Panowski S, Srinivasan S, Norwood K, Prashad S, Szenes V, Balakumaran A, Arandhya A, Lu W, Khan K, Borthakur G, Wang WL, Wang W, Soto LS, Vega F. CD70 Expression in Naïve Treated and Relapsed Acute Myeloid Leukemia Patients: A Potential Therapeutic Target in Relapsed Settings. USCAP, 2013. e-Pub 2013.
123. Leventaki L, Kunkalla K, Liu Y, Qu C, Agarwal N, Medeiros LJ, Vega F. Aldehyde dehydrogenase 1 (ALDH1) is a novel marker for tumor-associated macrophages and dendritic cells in mature B-cell lymphomas. Mod Pathol 26:341A, 2013. e-Pub 2013.
124. Qu C, Liu Y, Kunkalla K, Singh RR, Blonska M, Agarwal NK, Lin X, Vega F. Trimeric G protein-CARMA1 axis links smoothened to NF-κΒ activation in diffuse large B-cell lymphoma. AACR Annual Meeting, 2013. e-Pub 2013.
125. Qu C, Liu Y, Kunkalla K, Singh RR, Blonska M, Agarwal NK, Lin X, Vega F. Trimeric G protein-CARMA1 axis links smoothened to NF-κΒ activation in diffuse large B-cell lymphoma. AACR Annual Meeting, 2013. e-Pub 2013.
126. Agarwal NK, Qu C, Kunkalla K, Liu Y, Vega F. GLI1 Directly Regulates the Transcription of AKT Genes in Diffuse Large B-Cell Lymphoma. Blood 120(21), 2012. e-Pub 2012.
127. Leventaki L, Kunkalla K, Liu Y, Qu C, Agarwal N, Medeiros LJ, Vega F. Expression of Aldehyde dehydrogenase 1 (ALDH1) by tumor-infiltrating macrophages and dendritic cells in mature B cell lymphomas. Symposia on Cancer Research 2012: Immunology and Inflammation in Cancer, 2012. e-Pub 2012.
128. Alayed K, Kunkalla K, Qu C, Chakhachiro Z, Medeiros LJ, Singh R, Vega F. Glioma-associated oncogene homologue-3, a hedgehog transcription factor, contributes to the classical Hodgkin lymphoma microenvironment through the modulation of a subset of inflammatory chemokines and cytokines. Mod Pathol 25:321A, 2012. e-Pub 2012.
129. Leventaki L, Bourbon E, Qu C, Liu Y, Kunkalla K, Nguyen, Bueso-Ramos C, Singh R, Agarwal N, Vega F. Diffuse large B-cell lymphoma cells promote paracrine activation of NF-kB pathway in tumor-associated stromal cells. Mod Pathol 25:351A, 2012. e-Pub 2012.
130. Qu C, Liu Y, Kunkalla K, Agarwal NK, Vega F. Smoothened activates NF-kB pathway through PKCβ/CARMA1/TRAF6 activation and TRAF6 stabilization in diffuse large B-cell lymphoma. Blood(120A):1298, 2012. e-Pub 2012.
131. Qu C, Liu Y, Kunkalla K, Agarwal NK, Vega F. Smoothened activates NF-kB pathway through PKCβ/CARMA1/TRAF6 activation and TRAF6 stabilization in diffuse large B-cell lymphoma. Blood(120A):1298, 2012. e-Pub 2012.
132. Sanchez-Espiridion B, Figueroa V, Montalban C, Guisado P, Rodriguez ME, Canales M, Alves FJ, Vega F, Younes A, Morente MM, Tomas JF, Piris MA, Garcia FJ. MicroRNAs in advanced classical Hodgkin lymphoma:signatures with prognostic significance. 11th International Meeting of Malignant Lymphomas 22:152, 2011. e-Pub 2011.
133. Greaves WO, Sanchez-Espiridon B, Kunkalla K, Liang CS, Drakos E, Xiao L, Medeiros LJ, Vega F. Expression of the ATP-Binding Cassette Transporter MRP1 in Hodgkin/Reed-Sternberg Cells is Associated with Lower Treatment Failure - Free Survival in Classical Hodgkin Lymphoma. Lab Invest 91:299A, 2011. e-Pub 2011.
134. Kunkalla K, Qu C, Liu Y, Singh R, Vega F. The t(14:18)(q32:q21) Confers Resistance to Apoptosis-Induced by Smoothened Inhibitors In Diffuse Large B-Cell Lymphoma That Can Be Overcome by Functional Inhibition of BCL2. Blood 118A:1486-7, 2011. e-Pub 2011.
135. Qu C, Liu Y, Kunkalla K, Agarwal NK, Bourbon E, Pham LV, Ford RJ, Singh R, Vega F. Smoothened (SMO), a G-rotein-Coupled Receptor (GPCR) Activated by Hedgehog Ligands, Modulates the Activity Levels of PI3K/AKT and NF-Kβ in Diffuse Large B-Cell Lymphoma. Blood 118A:1062, 2011. e-Pub 2011.
136. Bourbon E, Qu C, Liu Y, Kunkalla K, Liang CS, Leventaki V, Martinez F, Singh R, Agarwal NK, Vega F. Diffuse large B-cell lymphoma cells promote paracrine NF-KB activation in stromal cells and monocytes that is mediated by the hedgehog receptor smoothened (SMO). Tumor Microenvironment Complexity - AACR, 2011. e-Pub 2011.
137. Qu C, Liu Y, Kunkalla K, Agarwal NK, Bourbon E, Pham LV, Ford RJ, Singh R, Vega F. Smoothened (SMO), a G-rotein-Coupled Receptor (GPCR) Activated by Hedgehog Ligands, Modulates the Activity Levels of PI3K/AKT and NF-Kβ in Diffuse Large B-Cell Lymphoma. Blood 118A:1062, 2011. e-Pub 2011.
138. Singh R, Kunkalla K, Greaves W, Vega F. Stroma-induced increase in ABCG2 Expression is involved in resistance to chemotherapy in diffuse large B-cell lymphoma. Blood 116A:428, 2010. e-Pub 2010.
139. Greaves WO, Kim JE, Kunkalla K, Medeiros LJ, Singh R, Vega F. Glioma-associated oncogene homologue-3 (GLI3): A novel marker for classical hodgkin lymphoma. Mod Pathol 90:289A, 2010. e-Pub 2010.
140. Greaves WO, Kim JE, Kunkalla K, Medeiros LJ, Singh R, Vega F. Hedgehog signaling pathway is aberrantly activated in a subset of high grade lymphomas. Mod Pathol 23:298A, 2010. e-Pub 2010.
141. Singh R, Kim JE, Kunkalla K, Vega F. Hedgehog signaling is a therapeutic target in diffuse large B-cell lymphoma. Keystone Symposia Conference, 2010. e-Pub 2010.
142. Sanchez-Espiridion B, Montalban C, Guisado P, Rodriguez ME, Canales M, Alves J, Vega F, Morente M, Tomás JF, Piris MA Garcia JF. MicroRNA expression signatures as prognostic markers in advanced classical hodgkin lymphoma. Blood 116A:1692, 2010. e-Pub 2010.
143. Garcia F, Sanchez-Espiridion B, Rodriguez ME, Canales M, Alves FJ, Vega F, Morente MM, Tomas JF, Montalban C, Guisado PM, Piris MA. miRNA expression signatures with prognostic significance in advanced classical Hodgkin lymphoma. European Association for Hematopathology, 2010. e-Pub 2010.
144. Buglio D, Palakurti S, Vega F, Neelapu S, Berry D, Ji Y, Myth K, Younes A. Inhibition of Tak-1 by AZ-Tak1 impairs NF-κB activation, downregulates XIAP and activates Caspase-9 inducing apoptosis in mantle cell lymphoma. Blood 116A:1175, 2010. e-Pub 2010.
145. Buglio D, Palakurti S, Vega F, Neelapu S, Berry D, Ji Y, Myth K, Younes A. Inhibition of Tak-1 by AZ-Tak1 impairs NF-κB activation, downregulates XIAP and activates Caspase-9 inducing apoptosis in mantle cell lymphoma. Blood 116A:1175, 2010. e-Pub 2010.
146. Singh R, Kim JE, Vega F. The ATP-binding cassette transporter ABCG2 is transcriptionally regulated by Sonic Hedgehog signaling pathway. American Association for Cancer Research (AACR) 69, 2009. e-Pub 2009.
147. Milito C, Khokhar FA, Newton K, Singh RR, Kasbidi F, Schlette E, Yao H, Biasoli I, Medeiros LJ, Jones D, Luthra R, Vega F. Extra Copies of GLI1 Gene at 12q13.12 Are Detected in a Subset of Cases of Trisomy 12 Negative Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphomas. Lab Invest 89:277A, 2009. e-Pub 2009.
148. Huh YO, Ketterling RP, Vega F, Kim JE, Medeiros LJ, Abruzzo LV. The t(14;19)(q32; q13)-Positive B-Cell Leukemia: A Comprehensive Genetic and Clinicopathologic Study of Six Cases. Mod Pathol 89:268A, 2009. e-Pub 2009.
149. Kim JE, Singh RR, Milito C, Cho-Vega JH, Karanikou M, Kasbidi F, Medeiros LJ, Luthra R, Vega F. Sonic Hedgehog Signaling Pathway as a Therapeutic Target in Diffuse Large B-Cell Lymphoma. Mod Pathol 89:271A, 2009. e-Pub 2009.
150. Cho-Vega JH, Davuduri R, Rivell G, Wang RY, Multani AS, Medeiros LJ, Ford RJ, Vega F. Identification and characterization of lymphoma stem cells in non-Hodgkin lymphoma cell lines. Mod Pathol 21:249A, 2008. e-Pub 2008.
151. Cho-Vega JH, Singh RR, Luthra R, Ma S, Davuluri Y, Drakos E, Rassidaki GZ, Medeiros LJ, Vega F. Sonic hedgehog signaling is activated by NPM/ALK in ALK-positive anaplastic large cell lymphomas. Lab Invest 88:249A, 2008. e-Pub 2008.
152. Konoplev S, Nguyen M, Huang X, Rassiddakis GZ, Garcia-Manero G, Yin CC, Amin H, Schlette E Lin P, Vega F, Admirand J, Huh Y, You J, Jorgensen JL, Kantarjian HM, Medeiros LJ, Bueso-Ramos C. Cytoplasmic expression of nucleophosmin does not predict favorable prognosis in AML patients. Lab Invest 88:260A, 2008. e-Pub 2008.
153. Vega F, Lennon PA, Luthra M, Jones D, Breeden M, Cho J, Medeiros L, Luthra R. Array-based comparative genomic hybridization (aCGH) of splenic and nodal marginal zone lymphomas (MZLs). Mod Pathol 20:262A, 2007. e-Pub 2007.
154. Huh Y, Vega F, Schlette E, Medeiros LJ, Abruzzo LV. MYC gene translocation in chronic lymphocytic leukemia. Lab Invest 87:245A, 2007. e-Pub 2007.
155. Tan M, Chen W, Jones D, Leventaki V, Medeiros LJ, Vega F. Histological and immunophenoitypical characterization of angioimmunoblastic T-cell lymphoma (AILT) involving the bone marrow. Mod Pathol 20:261A-62A, 2007. e-Pub 2007.
156. Cho-Vega JH, Vega F, Schwartz MR, Prieto VG. Expression of dicarbonyl/L-xylulose reductase (DCXR), a novel cell adhesion molecule, in melanocytic lesions. Lab Invest 86:78A, 2006. e-Pub 2006.
157. Vega F, Medeiros LJ, Abruzzo LV. T(8;13) positive "Bilineage lymphomas" with T-Cell and myeloid components: Report of 4 patients with the 8p11 myeloproliferative syndrome (EMS). Lab Invest 19:249A-250A, 2006. e-Pub 2006.
158. Vega F, Medeiros LJ, Atwell C, Cho JH, Tian L, Claret FX, Rassidakis GZ. Activation of mTOR signaling pathway contributes to tumoral cell survival in ALK-positive anaplastic large cell lymphoma. Blood 106(11):680A, 2005. e-Pub 2005.
159. Vega F, Medeiros LJ, Atwell C, Claret FX, Rassidakis GZ. Activation of mTOR and its downstream effectors in ALK plus anaplastic large cell lymphoma (ALCL). Mod Pathol 18:255A, 2005. e-Pub 2005.
160. Vega F, Kettlun C, Galvan D, Xu J, Zuniga TP, Diaz-Rohena DY, Sahu V, Donoso JA, Zubero A, Cicic D, Kadia M, Sampath D, Vega F. CDK9 Inhibition Enhances Venetoclax Activity and Prolongs Survival in a T-PLL Patient-Derived Xenograft Model.
161. Sahu V, Sainz TP, Kim KH, Dcunha N, Pan Y, Donoso JA, Mundhada AS, Mizuno H, Kettlun C, Basi AV, Gomez JA, Zubero A, Green M, Henderson J, Burks JK, Sampath D, Andreeff M, Mohanty V, Chen K, Vega F. Germinal center-like B-like cells seem to contribute to the pathobiology of human AITL through enhanced CD40:CD40L interactions.
162. Sainz TP, Pan Y, Basi A, Sahu V, Casassent A, Kettlun C, Mohanty V, Burks J, Chen K, Vega F. CD40 Expression in Macrophages and B-Cells Modulates Pathobiology in AITL Lymphoma Microenvironment. Advances in Molecular and Clinical Diagnosis for Haematological Malignancies.
163. Sainz TP, Pan Y, Basi A, Sahu V, Casasent A, Kettlun C, Mohanty V, Burks J, Chen K, Vega F. CD40 Expression in Macrophages and B Cells Modulates the AITL Tumor Microenvironment. Oral presentation at Experimental Hematopathology Committee Scientific Meeting.
164. Lee H, Ravizzini G, Aboismail E, Wixom J, Henderson J, Fayad L, Ahmed S, Nair R, Chauhan A, Westin J, Iyer S, Zaki A, Nze C, Vega F, Wang M, Flowers C, Malpica L. INTERIM PET-ADAPTED DE-ESCALATION CHEMOTHERAPY REGIMEN FOR ADVANCED STAGE cHL USING BRENTUXIMAB VEDOTIN, PEMBROLIZUMAB, DOXORUBICIN, AND DACARBAZINE. 18-ICML Lugano.

Book Chapters

1. Chadburn A, Du MQ, Said JW, Vega F. KSHV/HHV8-posiitve germinotropic lymphoproliferative disorder. In: Haematolymphoid tumours. Fifth edition. International Agency for Research on Cancer, 547-548, 2024.
2. Vega F, Bower M, Cesarman E, Chadburn A, Du MQ, Said JW. KSHV/HHV8-positive diffuse large B cell lymphoma. In: Haematolymphoid tumours. Fifth edition. International Agency for Research on Cancer, 545-546, 2024.
3. Amador C, Iqbal J, Tang SY, Vega F, Weinstock DM. Peripheral T cell lymphoma, Not Otherwise Specified. In: Haematolymphoid Tumours. Fifth edition. International Agency for Research on Cancer, 757-761, 2024.
4. El Huessein, Vega F. Precision Medicine in Diffuse Large B-Cell Lymphoma. In: Precision Molecular Pathology of Aggressive B-Cell Lymphomas. Springer, 179-211, 2024.
5. Nair R, Vega F, Iyer SP. Nodal peripheral T-cell lymphomas. In: The MD Anderson Manual of Medical Oncology. 4th. Mc Graw Hill, 2022.
6. Vega F. Peripheral T cell lymphoma NOS. In Tumors of the Lymph Node and Spleen. Atlas of Tumor Pathology of the AFIF (Armed Forces Institute of Pathology). In: American Registry of Pathology. 4th series, 2017.
7. Vega F. MALT lymphoma. In Tumors of the Lymph Node and Spleen. Atlas of Tumor Pathology of the AFIF (Armed Forces Institute of Pathology). In: American Registry of Pathology. 4th series, 2017.
8. Vega F. Mycosis fungoides. In Tumors of the Lymph Node and Spleen. Atlas of Tumor Pathology of the AFIF (Armed Forces Institute of Pathology). In: American Registry of Pathology. 4th series, 2017.
9. Vega F. Processing lymph node and spleen specimens. In Tumors of the Lymph Node and Spleen. Atlas of Tumor Pathology of the AFIF (Armed Forces Institute of Pathology). In: American Registry of Pathology. 4th series, 2017.
10. Vega F. Double hit lymphoma. In Tumors of the Lymph Node and Spleen. Atlas of Tumor Pathology of the AFIF (Armed Forces Institute of Pathology). In: American Registry of Pathology. 4th series, 2017.
11. Vega F. Systemic mastocytosis. In Tumors of the Lymph Node and Spleen. Atlas of Tumor Pathology of the AFIF (Armed Forces Institute of Pathology). In: American Registry of Pathology. 4th series, 2017.
12. Vega F. Adult T cell lymphoma/leukemia. In Tumors of the Lymph Node and Spleen. Atlas of Tumor Pathology of the AFIF (Armed Forces Institute of Pathology). In: American Registry of Pathology. 4th series, 2017.
13. Vega F. Infectious agents and lymphoma. In Tumors of the Lymph Node and Spleen. Atlas of Tumor Pathology of the AFIF (Armed Forces Institute of Pathology). In: American Registry of Pathology. 4th series, 2017.
14. Vega F. Normal anatomy and function of lymph nodes and spleen. In Tumors of the Lymph Node and Spleen. Atlas of Tumor Pathology of the AFIF (Armed Forces Institute of Pathology). In: American Registry of Pathology. 4th series, 2017.
15. Vega F. Extranodal NK T cell lymphoma. In Tumors of the Lymph Node and Spleen. Atlas of Tumor Pathology of the AFIF (Armed Forces Institute of Pathology). In: American Registry of Pathology. 4th series, 2017.
16. Vega F. ALK positive anaplastic large cell lymphoma. In Tumors of the Lymph Node and Spleen. Atlas of Tumor Pathology of the AFIF (Armed Forces Institute of Pathology). In: American Registry of Pathology. 4th series, 2017.
17. Vega F. T-cell histocyte rich large B cell lymphoma. In Tumors of the Lymph Node and Spleen. Atlas of Tumor Pathology of the AFIF (Armed Forces Institute of Pathology). In: American Registry of Pathology. 4th series, 2017.
18. Vega F. Burkitt lymphoma. In Tumors of the Lymph Node and Spleen. Atlas of Tumor Pathology of the AFIF (Armed Forces Institute of Pathology). In: American Registry of Pathology. 4th series, 2017.
19. Vega F. Myeloid neoplasm associated with FGFR1. In Tumors of the Lymph Node and Spleen. Atlas of Tumor Pathology of the AFIF (Armed Forces Institute of Pathology). In: American Registry of Pathology. 4th series, 2017.
20. Vega F. ALK negative anaplastic large cell lymphoma. In Tumors of the Lymph Node and Spleen. Atlas of Tumor Pathology of the AFIF (Armed Forces Institute of Pathology). In: American Registry of Pathology. 4th series, 2017.
21. Vega F. Angioimmunoblastic T cell lymphoma. In Tumors of the Lymph Node and Spleen. Atlas of Tumor Pathology of the AFIF (Armed Forces Institute of Pathology). In: American Registry of Pathology. 4th series, 2017.
22. Blieden, C, Agarwal, N, Vega, F. Microenvironment abnormalities and cytokine network deregulation in lymphomagenesis and progression, 34-50, 2015.
23. Blieden C, Agarwal NK, Vega F. Microenvironment abnormalities and cytokine network deregulation in lymphoma genesis and progression. In: Future Science Group, 2015.
24. Vega F. Hepatosplenic T-cell lymphoma. In: Diagnostic Pathology Spleen. Amirsys, 2014.
25. Vega F. Diffuse large B Cell Lymphoma. In: Familial Cancer Syndromes. Amirsys, 2014.
26. Leventaki, V, Vega, F. Lymphoid malignancies, 887-928, 2013.
27. Leventacki V, Vega F. Molecular Diagnostics of Lymphoid Malignancies. In: Essentials of Molecular Genetic Pathology. 2nd edition. Springer, 887-928, 2013.
28. Vega F. Intravascular large B cell lymphoma involving the skin. In: Neoplastic Dermatopathology. Amirsys, 2013.
29. Vega, F. Malignant lymphomas involving lung and pleura, 319-347, 2013.
30. Vega F. Lymphomas involving the lung and pleura. In: Diagnostic Pathology of Pleuropulmonary Neoplasia. Springer, 319-347, 2013.
31. Vega F. Intravascular Large B-Cell Lymphoma. In: Diagnostic Pathology: Skin Neoplasms. Amirsys, 2012.
32. Vega F. Primary Mediastinal Large B-Cell Lymphoma. In: Diagnostic Pathology: Pediatric Pathology. Amirsys, 2012.
33. Vega F. Intravascular Large B-cell Lymphoma. In: Diagnostic Pathology: Lymph Nodes and Spleen with Extranodal Lymphomas. Amirsys, 2011.
34. Vega F. Anaplastic Large Cell Lymphoma, ALK+. In: Diagnostic Pathology: Lymph Nodes and Spleen with Extranodal Lymphomas. Amirsys, 2011.
35. Vega F. Syphilitic Lymphadenitis. In: Diagnostic Pathology: Lymph Nodes and Spleen with Extranodal Lymphomas. Amirsys, 2011.
36. Vega F. B-cell Lymphomas with Features of Classical Hodgkin Lymphoma. In: Diagnostic Pathology: Lymph Nodes and Spleen with Extranodal Lymphomas. Amirsys, 2011.
37. Vega F. Diffuse Large B-cell Lymphoma, Centroblastic. In: Diagnostic Pathology: Lymph Nodes and Spleen with Extranodal Lymphomas. Amirsys, 2011.
38. Vega F. Primary Mediastinal (Thymic) Large B-cell Lymphoma. In: Diagnostic Pathology: Lymph Nodes and Spleen with Extranodal Lymphomas. Amirsys, 2011.
39. Vega F. Classical Hodgkin Lymphoma in Spleen. In: Amirsys, 2011.
40. Vega F. Plasmablastic Lymphoma. In: Diagnostic Pathology: Lymph Nodes and Spleen with Extranodal Lymphomas. Amirsys, 2011.
41. Vega F. Diffuse Large B-cell Lymphoma, Immunoblastic. In: Diagnostic Pathology: Lymph Nodes and Spleen with Extranodal Lymphomas. Amirsys, 2011.
42. Vega F. Inflammatory Pseudotumor Involving Lymph Node. In: Diagnostic Pathology: Lymph Nodes and Spleen with Extranodal Lymphomas. Amirysis, 2011.
43. Vega F. Hepatosplenic T-cell Lymphoma. In: Diagnostic Pathology: Lymph Nodes and Spleen with Extranodal Lymphomas. Amirsys, 2011.
44. Vega F. Author of multiple chapters. In: Diagnostic Pathology: Lymph Nodes and Extranodal Lymphomas. 2nd edition. Amirsys, 2011.
45. Vega F. Lymphomatoid Granulomatosis,. In: Diagnostic Pathology: Lymph Nodes and Spleen with Extranodal Lymphomas. Amirsys, 2011.
46. Vega F. T-cell/Histiocyte Rich Large B-cell Lymphoma. In: Diagnostic Pathology: Lymph Nodes and Spleen with Extranodal Lymphomas. Amirsys, 2011.
47. Vega F. Lymphomas and reactive diseases involving lymph nodes, spleen with extranodal lymphomas. In: Amirsys, 2011.
48. Vega F. Anaplastic Large Cell Lymphoma, ALK-. In: Diagnostic Pathology: Lymph Nodes and Spleen with Extranodal Lymphomas. Amirsys, 2011.
49. Vega F. Primary effusion lymphoma (PEL) and solid variant of PEL. In: Diagnostic Pathology: Lymph Nodes and Spleen with Extranodal Lymphomas. Amirsys, 2011.
50. Cho-Vega JH, Vega F. Essentials in Cancer Cytogenetics. In: Garcia-Foncillas, J editor. Molecular Biology in cancer, an approach to new therapies. Barcelona: Prouse Science, 1-27, 2009.
51. Vega, F, Jones, D. Molecular diagnostics of lymphoid malignancies, 655-674, 2008.
52. Vega F, Jones D. Molecular Diagnostics of Lymphoid Malignancies. In: Essentials of Molecular Genetic Pathology. Humana Press, 655-674, 2008.
53. Vega F, Toledo G. Alteraciones Anatomo-Patologicas de las Vias Aereas en el Asma bronquial. In: Asma Vision Actual. Aula Medica Ediciones, 33-54, 2001.
54. Idoate M, Vega F. Mecanismos Implicados en la Afectacion Cutanea por la Enfermedad de Injerto contra Huesped. In: Fisiopatologia de las Enfermedades Cutaneas II. Schering Plough, 281-303, 1999.
55. Cervera J, Vega F, Garcia-Tapia R. Estructura Histologica de las Cuerda Vocal. In: Diagnostico y Tratamiento de la Voz. Garsi, 48-53, 1996.
56. Cervera J, Vega F, Garcia-Tapia R. Lesiones Benignas de las Cuerdas Vocales. In: Diagnostico y Tratamiento de los Transtornos de la Voz. Garsi, 223-240, 1996.
57. Vega F, Panizo A, Pardo-Mindan FJ. Caracteristicas Biologicas de los Tumores. In: Enfermeria Oncologica. Ediciones Eunsa, 15-45, 1995.
58. Vega F. Revision de las clasificaciones de las neoplasias linfoides T. Que hay de nuevo?. In: Linfoma 360. Ambos Marketing (Spain).
59. Oo TH, Vega F, Rojas-Hernandez AC. Immune Thrombocytopenic Purpura Post Immune Checkpoint Inhibitor Therapy. In: Challenging Cases in Immunotherapy Related Organ Toxicities. Springer.

Books (edited and written)

1. Medeiros, O'Malley, Caraway, Vega F, Elenitoba-Johnson, Lim A. Tumors of the Lymph Node and Spleen; Atlas of Tumor Pathology of the AFIP (Armed Forces Institute of Pathology). Ed(s) 4th series. AFIP, 2017.

Letters to the Editor

1. Jain P, Nomie K, Kotlov N, Segodin V, Hill H, Ok CY, Fetooh A, Kanagal-Shamanna R, Vega F, Bagaev A, Fowler N, Flowers CR, Wang M. Immune-depleted tumor microenvironment is associated with poor outcomes and BTK inhibitor resistance in mantle cell lymphoma. Blood Cancer J 13: 156, 2023.
2. Chapman J, Vega F. Indolent ALK-negative anaplastic large-cell lymphoma, DUSP22 rearranged, with an unusual immunophenotype in a human immunodeficiency virus patient. Histopathology 70: 1173-1175, 2017.
3. Lamela J, Vega F. Immunologic aspects of chronic obstuctive pulmonary disease. N Eng J Med 361: 1024, 2009.
4. Lamela J, Vega F, Blanco J. Airway obstruction in chronic obstructive pulmonary disease. N Eng J Med 351: 1459-1461, 2004.
5. Vega F. Uterine Rupture. N Eng J Med 339: 268-269, 1998.